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Abbreviations of amino acids in appendix 1 
A  adenine 
ACTA1  the gene encoding skeletal 
  muscle specific -actin  
ACTN2  / 3 the gene encoding -actinin 
  2 / 3 
AD  autosomal dominant  
  inheritance 
ADP  adenosine diphosphate 
AR  autosomal recessive  
  inheritance 
ATP  adenosine triphosphate 
bp  base pair  
C  cytosine  
Ca2+  calcium ion 
CAPZA1 / 2 the gene encoding capping 
  protein 1 / 2 
CAPZB  the gene encoding capping 
  protein  
cDNA   complementary DNA 
CEPH  Centre d´Etude du  
  Polymorphisme Humain 
CFL2  the gene encoding cofilin 2 
CFTD  congenital fibre type  
  disproportion 
CM  cap myopathy 
cM  centi Morgan 
CNV  copy number variation 
DA  distal arthrogryposis 
DES  the gene encoding desmin 
dHPLC  denaturing high performance 
  liquid chromatography 
DMD  Duchenne muscular  
  dystrophy 
DNA  deoxyribonucleic acid 
DNM  distal nebulin myopathy 
e.g.  exempli gratia 
EM  electron microscope 
ESE  exonic splicing enhancers 
ESS  exonic splicing silencers 
etc.  et cetera 
FNLC  the gene encoding filamin C 
G  guanine  
HE  hematoxylin & eosin (stain) 
HGM  the human genome project 
i.e.  id est 
kb  kilobase   
kDa  kiloDalton 
KI  knock-in (mutation pointed 
  to a specific gene) 
KO  knock-out (gene function 
  silenced) 
LDM  Laing distal myopathy 
LGMD  limb girdle muscular  
  dystrophy 
LM  light microscope 
LMNA  the gene encoding lamin 
  A/C 
Mg2+  magnesium ion 
MLPA  multiplex ligation-dependent 
  probe amplification 
mm  millimeter 
MYO  the gene encoding myotilin 
m  micrometre  
mRNA  messenger ribonucleic acid 
MyBP-C  Myosin-binding protein C 
MYH  myosin heavy chain protein 
  encoding gene(s) 
MyHC  myosin heavy chain 
MYL  myosin light chain  
MYPN  myopalladin 
NEB  the gene encoding nebulin 
 
NEBL  the gene encoding nebulette 
n  the number of  
nm  nanometre 
NM  nemaline myopathy 
nt  nucleotide  
OBSCN the gene encoding obscurin 
p.  page 
PCR  polymerase chain reaction 
pH  pondus hydrogenii 
RNA  ribonucleic acid 
RT-PCR reverse transcriptase  
  polymerase chain reaction 
RYR1  the gene encoding  
  ryanodine receptor 1 
SEPN1  the gene encoding  
  selenoprotein 1 
SERCA  sarcoplasmic reticulum Ca2+-
  ATPase  
SH3  Src homology domain 
SLN  sarcolipin 
SNP  single nucleotide  
  polymorphism 
SR  sarcoplasmic reticulum 
SRF  the serum response factor 
SSCP  single-stranded  
  conformation polymorphism 
T  thymine  
TCAP  the gene encoding titin  
  capping protein 
TMD  tibial muscular dystrophy 
TMOD4  the gene encoding  
  tropomodulin 4 
TNNC  the gene(s) encoding  
  troponin C (calcium binding) 
  isoform(s)  
TNNI  the gene(s) encoding  
  troponin I (inhibitor)  
  isoform(s) 
TNNT  the gene(s) encoding  
  troponin T (tropomyosin 
  binding) isoform(s) 
TPM1  the gene encoding - 
  tropomyosinfast 
TPM2  the gene encoding - 
  tropomyosin 
TPM3  the gene encoding - 
  tropomyosinslow 
TTN  the gene encoding titin 
YL1  the gene encoding vacuolar 
  protein sorting 72 
WT  wild type 
ZASP  the gene encoding lim  
  domain-binding 3 







The aim of this thesis was to study the molecular genetics of nemaline myopathy and related 
disorders, and to investigate the molecular mechanisms by which the identified mutations 
cause muscle disease. This thesis comprises five publications on the molecular genetics, 
clinical features and histology of three different muscle disorders: nemaline myopathy, distal 
nebulin myopathy and cap myopathy. The molecular genetic studies performed led to the 
identification of mutations in three different genes encoding proteins of the thin filament of the 
muscle sarcomere: nebulin (NEB), and the tropomyosins slow and  (TPM3 and TPM2). The 
patients studied exhibited variable clinical and histological features, but the muscle biopsies 
all displayed disorganised sarcomeric Z discs and/or aggregates of proteins. 
Nemaline myopathy (NM) is a clinically and genetically heterogeneous group of 
disorders diagnosed on the basis of muscle weakness and the presence of protein 
aggregates called nemaline bodies or rods in the muscle fibres. Several genes are known to 
cause NM; these are NEB, slow skeletal -actin (ACTA1), TPM3, TPM2, troponin T1 
(TNNT1), and cofilin-2 (CFL2). In addition to these, there is at least a seventh NM gene yet to 
be identified. NM is usually the consequence of a gene mutation and the mode of inheritance 
varies between NM subclasses and different families. The disease can be inherited as an 
autosomal dominant or as a recessive trait. New dominant mutations in ACTA1, TPM2 and 
TPM3 are quite common also. The linkage and mutation analyses performed in this study 
included all known NM genes as well as several candidate genes. Mutations in NEB or TPM3 
were identified and published in 46 NM families. Including unpublished mutations a total of 
115 different NEB mutations have been identified in 96 families. 
Nebulin is a giant structural protein of the sarcomere which is encoded by NEB 
consisting of 183 exons, making mutation analyses demanding. Denaturing High 
Performance Liquid Chromatography (dHPLC) and sequencing proved to be efficient 
methods for the identification of heterozygous mutations along the whole length of the gene. 
In this study, the occurrence of one such mutation, deletion of the whole NEB exon 55 seen in 
the Ashkenazi Jewish population, was studied, and a haplotype segregating with this founder 
mutation, identified.  
In a project utilizing genome-wide and candidate gene analyses, a homozygous 
deletion disrupting the termination signal was identified in TPM3 in patients from two Turkish 
families. This is a likely founder mutation in the Turkish population. 
Distal nebulin myopathy (DNM) is a novel disorder identified in four Finnish families 
during the course of the present study. It is a recessively inherited myopathy causing distal 










NM histologically; the biopsies of the patients did not display nemaline bodies in routine light 
microscopy, although some of them had small Z-disc-derived protein aggregates visible under 
the electron microscope. Two different homozygous mutations leading to the substitution of 
an amino acid in nebulin were found to underlie DNM. Both of the mutations were known to 
cause NM in compound heterozygous form, together with another, more disruptive NEB 
mutation. This study showed that NEB mutations may cause disorders other than NM. 
Cap myopathy (CM) was described as a novel entity already in 1981. It is 
characterised by massive protein aggregates and disorganised sarcomeres forming cap-like 
structures under the muscle cell membrane on one side of the fibre. This disorder is variable 
and may overlap with NM both clinically and histologically. The patients may have nemaline 
bodies either within the cap structure or elsewhere in the fibre. The heterozygous de novo 
dominant in-frame deletion of one codon in TPM2 described in the present study was the first 
genetic cause involved in CM. 
NM, DNM and CM patients have variable clinical pictures in terms of both severity, 
distribution of affected muscles and age of onset. These may differ between and within the 
disorders as well as between individuals with mutations in the same genes, or even between 
patients sharing the same mutation. On the other hand, it is notable that patients with different 
diagnoses or causative genes may exhibit an overlap in their histological and/or clinical 
features.  
The exact molecular mechanisms behind these disorders remain to be elucidated, but 
it is possible that some of the overlap could be explained by shared pathogenetic pathways. 
Based on the present study, these mechanisms might include altered interactions of the 
abnormal proteins with their binding partners within the sarcomere. 
 
Review of the literature                                                                     
1 Principles of molecular genetics and gene identification 
Medicine and biology have always fascinated philosophers and scientists, and even today 
science relies on observations made during previous centuries: Carl Linnaeus created 
taxonomy, a system of ecological classification of species and published Systema naturae in 
1759.1, 2 Charles Darwin studied the hypothesis that organisms have evolved from the same 
origin, and published his On The Origin of Species  in 1859, setting the basis for evolution.3 
How new species arise, what causes variation within a species and why members of a 
population often are alike was, however, not at the time understood. In 1865 Gregor Mendel 
carried out and described the first detailed formulas of inheritance,4-6 and in 1909 Wilhelm 
Johannsen coined the term gene as the unit of heredity, and demonstrated that environmental 
adaptations are not inherited.7 Genetics were molecularised in 1944 when Oswald Avery, 
Colin MacLeod, and Maclyn McCarthy8 showed that genetic information, i.e. the material 
inherited from parent to offspring, is DNA. The molecular structure of DNA was resolved in 
1953 by James Watson, Francis Crick and Rosalind Franklin who revealed DNA to be a 30 
nm long ladder-like double helix in which the steps are formed by base pairs. Human DNA 
contains 3.2 billion base pairs. Their work made possible the understanding of inheritance 
and evolution at the molecular level. Genes are the recipes for thousands of different proteins 
encoded in DNA using four different bases (Adenine, Thymine, Cytosine and Guanine).9 In 
1956 Joe Hin Tijo and Albert Levan showed that human DNA is packed in the nucleus of each 
cell of a human body into 46 chromosomes (23 of them inherited from each parent).10-12  
The major approaches used in molecular genetics are DNA amplification by 
polymerase chain reaction (PCR) and sequencing, i.e. reading through the genetic code of 
DNA.13-16 In addition, cloning and recombinant technologies provide essential tools for 
biomedical research today.17, 18 Research into the life sciences has developed at enormous 
speed during the past decades, and subsequently, knowledge in medicine and biology has 
increased exponentially.19 This can be demonstrated unscientifically by viewing the articles in 
PubMed database; in the year 1950 the number of publications was 81580, in the year 1970, 






1.1 Genes and polymorphisms 
DNA contains coding units, i.e. genes, which are first transcribed into mRNA molecules which 
in turn are usually translated into proteins, and elements regulating gene expression. Most 
genes have more than one expression pattern i.e. possess the ability to produce multiple 
proteins; the same gene may produce slightly different proteins in different tissues.21, 22 Thus, 
genes define the function of each cell, allowing them to specialise into over the 300 different 
cell types found in the human body, for example neurons in the brain or osteoblasts in the 
bones. Together cells form tissues and organs.23 Cells send and receive signals which 
instruct them to express the correct genes when needed.24 Only a proportion of the genes are 
functional in each tissue, i.e. those encoding exactly those proteins needed in the cells of that 
tissue. The remaining genes may be functional at another point in time or expressed in other 
cell types.25 
In addition to genes, the genome contains polymorphic (Greek: “having multiple 
forms”) regions which contain the normal variation making us individuals. Polymorphisms are 
inherited according to the same principles as genes, and if close to (or within) the gene,  they 
provide a useful tool kit for identifying a gene underlying a particular phenotype.26-29 The 
polymorphic markers most often used for this purpose to date are microsatellites and single 
nucleotide polymorphisms (SNPs).30-32 Microsatellites are short tandem repeat segments of 
DNA sequence (e.g. CTn) providing several possible genotypes according to the length of the 
tandem repeat. Microsatellites have been estimated to comprise 3 % of the human genome.33 
The human genome contains an estimated 10 million SNPs of which 3 million have been 
identified.22, 31 The importance of copy number variation (CNV), i.e. gains and losses of DNA 
segments, has only recently been acknowledged. CNVs have long been associated with 
disorders caused by chromosomal rearrangements, but recent twin studies have shown that 
otherwise identical healthy twins may have different copy numbers of DNA segments. Many 
CNVs include genes and thus, a copy number of a gene can vary between zero and ten. This 
observation suggests that CNVs may have a significant contribution to evolution, and to 
normal genetic and phenotypic variation due to the different expression levels of genes.34 
CNV arises during mitosis and studies on mouse embryonic stem cells have indicated that all 
somatic tissues in individuals can be CNV mosaics.35 The non-coding, 95 %, of the genome 
was believed to be unimportant “junk DNA”, but currently it seems likely that it contains 






1.1.1 Projects elucidating the genomic organisation of human and other 
organisms 
In the year 1990, the sequencing of the whole human genome was launched as a massive 
international collaborative project, the Human Genome Project (HGM).38, 39 By the year 2004 
nearly 100 % of the gene-rich euchromatic human genome had been sequenced, and the 
physical and genetic maps created revealed the locations of 20 000 - 25 000 genes.22 In 
addition, the HapMap-project31 is identifying the locations and variations of SNPs in human 
sequences. Another project is identifying and locating CNVs of more than 1 kb in the human 
genome.40 In addition to the human genome, genomes of other species have been and are 
being sequenced.41, 42 These projects have enormously eased the work of the molecular 
geneticist trying to identify novel genes underlying a disease. Today, the identification of 
disease genes depends to a great extent on the physical and genetic maps of these genomes 
available in databases (e.g. NCBI) on the internet. 
1.2 Mutations 
Mutations, unlike polymorphisms, are changes in DNA which result in failed function of the 
gene or gene product, interfering with the sensitive system of the tissue or tissues where the 
mutated gene is expressed. External factors, such as radiation or chemicals, may cause novel 
changes in the DNA of somatic cells or gametes. Somatic mutations may cause disease, for 
example cancer, but may also be responsible for harmless variation as well. It is this kind of 
variation in gametes which gives rise to variation between individuals and makes evolution 
possible.32, 36 If a new disease-causing mutation occurs in an egg or in sperm, giving rise to a 
new individual, this person may have a genetic disorder caused by that mutation.43, 71 
 
In general, mutations often cause under- or over-expression of the gene product or 
alter its structure which leads to a failure of function and a disorder. Recessive mutations 
have been estimated to be 4:1 more common than dominant ones.72, 73 This is, however, 
biased in favour of mild dominantly inherited disorders.74 There are several ways in which a 
mutation can lead to altered function: Loss-of-function mutations are often recessive 
mutations causing a complete loss or reduced activity of the gene product underlying the 
disorder, i.e. the normal allele in heterozygous carriers produces enough of the gene product 
for the proper function. Haploinsuffiency refers to a heterozygous loss-of-function dominant 
mutation which results in half the quantity of gene product and causes phenotypic effects. 
Gain-of function mutations are dominant mutations which lead to increased levels of gene 





mutations are common in proteins which form dimers or multimers, e.g. actin, tropomyosins 
and collagens. These altered gene products interfere with the function of the normal gene 
product.25, 74 
Point mutations are mutations in DNA where one base of a nucleotide in changed to 
some other. Within the exon this may result in a missense, nonsense, silent or splicing 
mutation. A missense mutation substitutes one amino acid for another, often leading to an 
altered and disrupted conformation of the protein product. Nonsense mutations cause 
premature termination signals (TAA/TAG/TGA). Missense, nonsense and silent mutations in 
exons may also disrupt exonic splice signals such as exonic splicing enhancers (ESE) and 
silencers (ESS), and cause aberrant pre-mRNA splicing.75-78 Splice-site mutations, however, 
are usually intronic mutations found in the acceptor or donor splice signals at exon-intron 
boundaries, or at branch-sites.75, 79 Deletions and insertions, such as duplications within the 
exon usually cause a shift in the reading frame of the gene leading to a misread protein tail 
and a premature termination signal in the mRNA, but some of them are in-frame mutations 
evoking deletion or insertion of additional amino acids in to the protein without disrupting the 
reading frame.25 Deletions or insertions in the intron may cause errors in the splicing patterns 
of the gene if regulatory elements of splicing are disrupted.79 Missense mutations are 
approximately three and nonsense mutations six times more frequent than 
deletions/duplications/insertions and splice site mutations.25, 43  
Mutations in genes essential for life may cause lethal or very severe disorders while 
genes which can either cope with the mutation or have several isoforms to compensate for 
the function of the faulty gene product, often cause milder disorders. When mutated, 
“housekeeping” genes expressed in several or even all tissues evoke multi-organ disorders, 
while genes specific to a particular tissue cause tissue-specific disorders.43 
1.3 Modes of inheritance 
There are four Mendelian modes of inheritance: autosomal (22 human non-sex chromosomes 
inherited from both parents) dominant (AD) and recessive (AR), X-linked (female sex 
chromosomal inheritance: females inherit one X-chromosome from each of their parents, 
males only one from their mothers) and Y-chromosomal (male sex chromosomal inheritance: 
present in and inherited from males only). Many textbooks separate dominant and recessive 
X-linked disorders as their own modes of inheritance, but since no true recessive X-linked 







A mutation in one allele is called dominant if it alone causes a disorder and recessive 
if mutations in both alleles are needed in order for the disorder to appear. In the case of 
dominant inheritance, one of the parents expresses the trait or disorder and has a 50 % 
possibility of passing it on to his/her offspring. The parents of a patient with a recessively 
inherited disorder are usually unaffected, while on average 25 % children are affected, 50 % 
are unaffected mutation carriers, and 25 % unaffected, not carrying the mutation.25 Mutations 
can also be newly arisen, i.e. de novo mutations not seen in either of the parents. If such a 
mutation evokes a condition, it is a new dominant mutation.43  
The whole concept of inheritance is, however, becoming more complicated and not all 
traits or disorders are inherited by Mendelian laws. For example in complex, multifactorial and 
polygenic disorders (such as autism and diabetes)44, 45 the influence of more than one gene, 
environmental factors and normal genetic variation is recognised, but not yet well 
understood.46 In addition, mutations in mitochondrial DNA,47, 48 mosaicism (a mutation which 
is expressed in some, but not all, cells),49, 50 X-chromosome inactivation and epigenetic gene 
silencing51, 52 (epigenetic = gene expression is affected by mechanisms other than changes in 
the DNA sequence, e.g. gene silencing by promoter methylation) also show non-Mendelian 
inheritance. Chromosomal changes such as duplications or deletions of whole, or parts of, 
chromosomes are also the cause of several disorders. The most common chromosomal 
disorder is Down syndrome, i.e. trisomy of chromosome 21.53  
The mutations described in this thesis are AR or AD or de novo mutations.  
1.4 Gene identification 
 
When a gene for a hereditary disorder is to be identified, the family history of the patients 
must be investigated and pedigrees drawn up. The more information that can be gleaned 
from several generations of family members, the more informative is the pedigree when 
elucidating the mode of inheritance. The mode of inheritance usually prescribes the 
subsequent methods to be used.28 Sometimes knowing the population to which the patient 
genetically belongs, is helpful. For example, if the family shows AR inheritance and the family 
is consanguineous (the parents are relatives) or from an isolated population such as the 
Finns, this often indicates that the mutation is homozygous, i.e. the affected child has 
inherited the same mutation from both parents.54, 55 If the family is not consanguineous, but 
has many affected members (familial occurrence), samples also from unaffected relatives are 
useful in further studies to exclude candidate genes and to identify linkage. This is the case 
even if the mutation inherited from the mother is different from that inherited from the father, 





1.4.1 Genetic linkage and linkage analyses 
Linkage can be defined as “the tendency of genes or other DNA sequences at specific loci 
(locations in the chromosome) to be inherited together as a consequence of their physical 
proximity on the same chromosome”.25 In other words, the closer the loci of the sequences 
are to each other in a chromosome, the more likely they are to be inherited together. This 
phenomenon can be utilised in disease gene identification based on the assumption that the 
disease gene is inherited together with a polymorphic marker more often than would be the 
case for independently inherited elements – in other words, these sequence elements are 
linked. Furthermore, recombination (crossing over between homologous chromosomes) 
between the two loci is more unlikely the closer the loci are to each other. Genomic distances 
can be measured by physical distances using base pairs or by genetic distances, i.e. 
centiMorgans (cM), which equals a 1 % probability of recombination in the formation of 
gametes via meiosis. If a distance between two loci is 10 cM, recombination between these 
sites occurs in 10 % of meioses.25, 28 
Linkage analysis is used to identify the genomic regions shared between the 
members of a family/isolated population affected with a genetic disorder utilising polymorphic 
variation.28, 30 Haplotypes are created for each family member by arranging their polymorphic 
markers on a physical map (haplotyping). These maps can be created by analysing 
fluorescently labelled markers using fragment analysis, but today, especially genome-wide 
analyses are usually performed using SNP arrays. If the material to be analysed is small, i.e. 
consists of one or a few families and few markers used, it is sometimes possible to detect 
positive (haplotypes are shared by the patients and none of the unaffected family members 
have the same set of haplotypes) or excluding (healthy and affected family members share 
the same haplotypes or the affected family members have different haplotypes) linkage by 
viewing the data.56, 57 Most often, however, mathematical tools are needed to verify the result 
and to calculate the probability of linkage, especially if the material to be analysed is large, 
consisting of dozens of families and perhaps covering the whole genome (genome-wide 
linkage analysis).58  
The mathematical measurement for the likelihood of linkage is the lod score which is 
the logarithm of the likelihood (logarithm of odds) for the linkage, assuming the inheritance 
follows Mendelian laws, and taking into account the recombination fraction (). Recombination 
fraction means the proportion of the meioses in which a given pair of loci are separated by 
recombination. If the lod score is +3 or more, the region can be considered to be linked (to the 
disorder), and if -2 or below, linkage can be said to be excluded. The lod score can be 








probability of birth sequence with a given linkage value






 = recombination fraction 
N = number of non-recombinant offspring 
R = number of recombinant offspring 
 
The success and reliability of linkage analysis is dependent on the markers chosen, 
the number and the variation of the markers, the individuals analysed and the mathematical 
approach chosen.26, 27, 58, 59 The number and types of markers included in the analysis are of 
major importance. Microsatellite markers carry more variation compared with SNPs, but the 
distance between them in genome-wide analysis is usually 10 cM which is often too sparse 
for identification of linked regions, and therefore denser, for example 1 cM distance SNP 
scans are more efficient.27, 59, 60  
There are different ways to perform meiotic mapping and linkage analyses when 
attempting to identify a gene. The most common methods are: 1. Parametric (model-based) 
two-point or multipoint lod score analysis, 2. Non-parametric (model-free) two-point or 
multipoint lod score analysis, and 3. Association studies. Generally speaking, the two-point 
linkage analysis evaluates the linkage between the disease locus and the marker, and it is 
usually the method of choice when analysing candidate gene loci with only a relatively small 
number of markers and family members.61 Multipoint linkage analysis examines the linkage 
between the disease locus and more than one marker simultaneously, which overcomes the 
errors caused by uninformative markers.62, 63 This is useful when analysing for example 
genome-wide SNP data. Association studies are effective when analysing data of complex 
diseases.64 Parametric analyses are more reliable but require a knowledge of inheritance and 
other parameters. Non-parametric analyses rely more on calculated likelihood on the basis of 
data with less background information. When analysing incomplete data, non-parametric 
single point analysis or the multipoint approach, is the method of choice.63  
The term linkage equilibrium refers to the situation where a mutation is specific for one 
family, i.e. several families may be affected by the same disorder caused by mutations in the 
same gene but have different mutations and haplotypes segregating with the mutation. 
Linkage disequilibrium points to situations where all the families with a certain disorder share 
the same mutation and haplotype segregating with the disorder in question. This is a typical 
phenomenon in isolated populations, and homozygous areas shared by all the affected 
patients are sought in order to identify the causative gene. The method is called 






1.4.1.1 Computational tools in linkage analysis 
Today, researchers have multiple different types of mathematical applications to choose from 
in order to create haplotypes and calculate lod scores from their “raw” genotype data. The 
calculation of the lod score is challenging because the calculation of the likelihood for 
recombination is very complicated.28 Bioinformatics provide several efficient tools to create 
pedigrees and haplotypes and there also are programmes to carry out the massive 
arithmetical operations involving several variables (such as consanguinity, modes of 
inheritance, penetrance, gene frequencies, distances of the markers used) when analysing 
the linkage data. Some (parametric) mathematical and computational approaches are purely 
logical and rule-based, but some (non-parametric) are based on likelihood and/or conditional 
probabilities.56, 62, 62 For example MLINK (LINKAGE toolkit) is useful when calculating two-
point lod scores.65, 66 Genehunter calculates multipoint lod scores involving dozens of markers 
in complex pedigrees. Inheritance information in Genehunter allows the reconstruction of 
maximum-likelihood haplotypes for all individuals in the pedigree, but due to the more 
complex mathematical operations of the multipoint lod score, the pedigree size must be 
moderate.62, 67 Merlin is used for non-parametric multipoint linkage analysis. It has the ability 
to detect genotyping errors and omit the uninformative data.68 
1.4.1.2  Linkage analysis utilizing genetic maps 
The candidate region(s) for a disorder provided by genome-wide linkage analysis are usually 
first roughly delineated and then narrowed further by analysing more markers in the promising 
areas detected.25 When a candidate region has been identified, the genetic maps begin to 
play an important role.38 The genes in the candidate regions, their expression patterns and 
possible functions are scrutinised, and those playing a role in the affected tissue and in the 
particular mechanism believed to be disturbed in the disorder under study, are chosen for 
mutation analysis. Nowadays this information can be found in public databases. 
1.4.2 Candidate gene approach 
Understanding the molecular biology of the affected organ or tissue is important when 
attempting to identify a causative gene for a phenotype. The histology of the affected tissue, 
the mode of inheritance and the clinical symptoms can also provide valuable hints, indicating 







Naturally occurring and gene-modified, knock-in (KI) (mutation pointed to a specific gene) and 
knock-out (KO) (gene function silenced) animal models can also provide valuable information 
and clues to the possible causative genes when expressing phenotypes and/or histology 
similar to the disorder being studied.69, 70 Today, expression arrays play an important role in 
elucidating the expression patterns of different genes in different tissues. Sometimes it is 
possible to identify a gene based on these data, alone, and no linkage analysis needs to be 
performed. In addition, not all families are suitable for linkage analysis. This is the case if a 
DNA sample is available only from the affected child of a non-consanguineous family, there is 
no knowledge of the mode of inheritance, or the mutation is likely to be de novo.28 In these 
cases, the candidate gene is analysed directly for the mutations. 
1.5 Mutation identification 
Identification of the disease-causing mutations is often important for the diagnosis, and the 
family concerned. From the biological point of view, characterising the gene and the mutation 
causing the condition provides valuable information on the function of the gene. The most 
common and straight-forward method for mutation identification in both genomic and 
mitochondrial DNA is sequencing.14, 15 If the gene does not express several isoforms in the 
tissue studied and if the geneticist has access to the tissue affected, the mRNA of the gene 
can be extracted from the tissue, converted to complementary DNA (cDNA) using RT(reverse 
transcriptase)-PCR and sequenced, reducing the length of the DNA fragments that need to be 
analysed.  
When analysing large genes with tens or hundreds of exons, or a large number of 
patient samples, a pre-screening method for genomic changes in the DNA is preferred. In 
addition, several methods have been developed in order to detect different types of 
mutations. These kinds of mutation screening methods are for example SSCP (Single-
Stranded Conformation Polymorphism), dHPLC (denaturing High Performance Liquid 
Chromatography) and MLPA (Multiplex Ligation-dependent Probe Amplification).  
SSCP is based on different secondary conformations of denatured DNA single-strand 
fragments containing a SNP or a mutation when the fragments move in an electric field 
towards the positively charged end in a non-denaturing polyacrylamide gel.80 The method was 
previously widely used for mutation and SNP detection, but since it is such a time-consuming 






dHPLC detects small heterozygous variations in heteroduplex DNA fragments. The 
principle of the method is presented in Figure 1: Heteroduplex fragments are produced by 
denaturing PCR-fragments using heat followed by slow cooling. This leads to the formation of 
heteroduplex and homoduplex DNA fragments when a heterozygous mutation (or SNP) is 
present in the sample DNA. Due to the different chemical properties and charges of the 
homo- and heteroduplexes, they adhere differentially to the hydrophobic electrostatically 
neutral matrix of the stationary phase (polystyrene-divinylbenzene copolymer beads in the 
column of the chromatography), and elute with the hydrophobic buffer (acetonitrile-TEAA-
buffer - a running liquid phase) from the column at different time points. This is detected by an 
inbuilt spectrophotometer, and seen as peaks in the chromatograms.82, 83  
 
 
Figure 1. The principle of dHPLC. A. Formation of the heteroduplexes by heating and slowly 
cooling the PCR-product. B. Separation of the hetero- and homoduplexes in the column of the 
dHPLC. (Transgenomics Inc) C. Chromatogram peaks of optimised standard samples. D. An 
example of the mutation seen in a patient and his mother. The curve produced by the fathers 
sample resembles the wild type and he does not carry the mutation. The frameshift mutation 
identified shown in the nucleotide sequence. 
 
 
dHPLC is able to scan hundreds of samples a day and when the analysis 
temperatures for each fragment are optimised carefully, it is a reliable method for screening 
mutations.84 Several variations of this method have been developed for e.g. detection of 
mitochondrial mutations or mutational mosaicism.85  
Large copy-number changes consisting of larger segments of genomic DNA covering 
one or multiple exons cannot be detected by the above methods. When such mutations are 






based on the hybridisation of labelled cDNA probes to restriction enzyme-digested and 
subsequently size-separated target DNA transferred to a filter membrane.86, 87 In MLPA, a 
copy is made of each target sequence by hybridisation of two probes to the target DNA and 
ligating them. The target sequences are amplified in a multiplex-PCR reaction using universal 
fluorescent-labelled primers. The PCR fragments are analysed by fragment analysis methods, 
and the relative copy numbers of the target are calculated.88 Like dHPLC, MLPA also has 
several applications, e.g. for detection of variations in the methylation patterns of a gene.89 
High-throughput sequencing and microarrays provide more advanced mutation 
identification tools utilising the latest and rapidly developing technologies for mutation 
detection and expression studies. With high-throughput sequencing, the whole genome can 
be analysed relatively quickly. This can, for example, be performed in a system where 
multiple DNA segments are bound to microscopic beads and amplified in one reaction 
(pyrosequencing or sequencing-by-synthesis), and the sequence analysis is automated by 
the software comparing the reference sequence to the sequence analysed.90 Microarrays are 
chip-based systems where, for example, wild-type DNA probes (such as the exons of a gene) 
are bound to the membrane of the chip and the DNA studied is hybridised to it. The level of 
the affinity of the hybridisation is analysed using bioinformatic tools. The expression of a gene 
studied can be analysed by hybridising mRNA to the probes bound to the membrane.91, 92 
1.5.1 Verification of the mutation 
When a possible mutation has been identified, it is first verified by analysing control DNA 
samples from healthy individuals. Evaluation of the conservation of the change, especially of 
a point mutation, is performed by comparing the amino acid sequence to animal orthologs, 
and in the case of missense mutations, to protein homologues using computational database-
based BLAST tools.93 It is assumed that the more conserved the amino acid is between 
different species is, the more relevant it is for the function of the gene.25  
RT-PCR reveals the outcome of the mutation at the mRNA level. Faulty mRNA can 
lead to an altered protein product, but the RNA may also be degraded before being translated 
into protein. The expression levels of the gene can be studied using RNA-based methods, for 
example by northern blotting and TaqMan (real-time PCR-method developed to quantify 
differences in mRNA expression).94, 95 If possible, the effects of the mutations identified in 
genes should be studied in the protein. Alternatively, the change caused by the mutation can 
be predicted by computer programmes designed for detecting possible misfolding or loss of 
important domains in the protein. Western blotting is the method for primary analysis of 






according to their size. Two-dimensional gels (with pH gradient in one and size separation in 
another direction) can be used to investigate changes in the polarity and conformation of the 
protein. Several approaches such as two-hybrid methods have been developed to study the 
binding of proteins to their targets (enzyme-substrate or multimerisation studies). In addition, it 
is possible to analyse the amino acid sequences of the protein by mass spectrometry-based 
tools.43 
2 Muscle tissue 
According to the body and trace fossils found in the White Sea, it has been estimated that the 
evolution of the muscle tissue began 555.3  0.3 million years ago to meet the requirements 
of locomotion.96 Studies by computational tools on reconstructed phylogenetic trees and 
analysis of the six genes expressed in muscles suggest that the cardiac and skeletal muscle 
tissues share a common (genetic) ancestor which existed already before the divergence of 
the arthropods (e.g. spiders, insects) and the vertebrates, while smooth muscle seems to 
have evolved independently, and is believed to be the most primitive type of muscle tissue. 
Today, invertebrates have smooth and skeletal muscle tissues, while vertebrates have, in 
addition, a specialised cardiac muscle tissue found in heart97 (personal communication with 
Prof. Frank Corsetti). In humans, there are approximately 650 muscles producing force for the 
movement of the human body and its internal organs with their own histological and functional 
characteristics.43  
Skeletal/striated muscles (Fig 2), comprising 40 % of the human body mass, are 
usually attached to bones by tendons. Skeletal muscle is built up of cylindrical units inside 
one another: the muscle is formed of bundles of fascicles surrounded by thin layers of 
connective tissue. Fascicles are formed of bunches of muscle fibres ( = 0.01 – 0.1 mm), 
which in turn are packed with myofibrils ( = 1 - 2 µm). Myofibrils again are formed of the 
smallest units of the muscle bundled together, i.e. highly organised contractile units, the 
sarcomeres. The sarcomeres are responsible for the striated appearance of the skeletal 
muscle tissue. Actin and myosin filaments are the main components of the sarcomere. Muscle 
fibres (Fig 3A) have multiple subsarcolemmal (cell membrane) nuclei sometimes difficult to 
distinguish from satellite cells which are small mononuclear progenitor cells found between 
the sarcolemma  and basal membrane. These cells are able to differentiate into new fibres. 







Figure 2. The organisation of the skeletal muscle. (Figure kindly provided by Professor 
Sandra K. Ackerley, University of Guelph, Canada) 
 
 
Smooth muscle, found for example in the walls of the blood vessels and internal 
organs contracts involuntarily and very slowly, often in response to signals from the 
autonomic nervous system. It comprises 3 % of the body mass. The smooth muscle cell has a 
single central nucleus and the cells form neat parallel but less organised structure than 
skeletal muscle cells (Fig 3B). Cardiac muscle is unique to the heart (Fig 3C). It shares 
features with both skeletal and smooth muscle; it is striated and multinucleate, but the nuclei 
are centrally located. One feature unique to cardiac muscle is the presence of branched cells 
which are joined to one another via intercalated discs, making sequential contraction of the 




Figure 3. A. Skeletal muscle 1. a single fibre, 2. a satellite cell, 3. a nucleus. B. Smooth 
muscle tissue  C. Cardiac muscle 1. a single cell, 2. nuclei, 3. intercalated discs. (Adapted 





2.1 Skeletal muscle fibre types 
Skeletal muscle fibres have specialised as oxidative (red) slow twitch, type I (or 1) fibres and 
glycolytic fast-twitch, type II (or 2) fibres (Fig 4A). Type I fibres are dominant in large muscles 
rich in mitochondria and myoglobin, and responsible for most of the aerobic long term/static 
activity. Type II fibres are divided into subtypes: Type IIA fibres can create energy by both 
aerobic and anaerobic metabolism, type IIB (white) fibres use anaerobic metabolism to create 
energy for producing powerful bursts. They have high contraction frequencies but they fatigue 
quickly. This fibre type is dominant in rodents. Type IIX is the fastest muscle fibre type, being 
able to contract most quickly and to use anaerobic metabolism to generate short-term power. 
The tiring of type IIX fibres during bursts of activity causes the pain nicknamed “lactic acid 
pain”. The fibre type is determined by the type of neuron which innervates the muscle, and 
fibres of different types have different gene expression patterns. All muscle fibres of a motor 
unit are of the same type (Fig 4B).98, 100 
 
Figure 4. A. Type I, IIA and IIB/X fibre seen in a cross-section of rat skeletal muscle tissue. B. 
Innervation (pointed by an arrow) seen in longitudinal section of skeletal muscle fibres. 
(Figures kindly provided by Prof. Roger Wagner, University of Delaware, USA) 
2.2 The skeletal muscle sarcomere  
 
Microarray studies on skeletal muscle have estimated that some 3500 genes are expressed 
in this type of tissue. At least 1000 genes of these are believed to be specific for muscle 
tissue and essential for muscle cells, and most of them encode proteins for the sarcomeres. 
The largest proteins encoded by the largest genes (such as titin, nebulin and obscurin) in 





Figure 5. A. The structure of the muscle sarcomere: Actin molecules in green, myosin 
molecules in red, tropomyosin and nebulin molecules as black lines spanning the thin (actin) 
filaments. Thin filaments in muscle sarcomeres are anchored at the Z-disc by the cross-linking 
protein α -actinin (orange) and are capped by CapZ seen in pink in the Z discs. The thin-
filament pointed ends terminate within the A band and are capped by tropomodulin (bright 
red). Myosin-binding protein C (MyBP-C) as vertical yellow lines. Titin (the third filament 
system) is in turquoise. (Reprinted from Gregorio et al.,2000, Trends in Cell Biology, with 
permission from Elsevier) B. Electron microscopic view of a sarcomere (Reprinted from 
Ottenheijm et al., 2008, Respiratory Research with permission of BioMed Central) 
 
The basic structure of the sarcomere has been known for decades,106, 107 but many 
structural and functional details remain to be resolved even today. The sarcomere consists of 
a meshwork of hundreds of structural proteins, and proteins functioning in signalling cascades 
between the sarcolemma and the sarcomere and in contraction (Fig 5A and 6).108 The 
sarcomere can be divided into sections according to the bands seen under the electron 
microscope (EM) (Fig 5B). The thin filament is attached to the Z disc and extends to the I 
band seen in the EM view as a pale section next to the Z disc ending at the A band of the 






third filaments overlap and interact. Here the molecular events of the muscle contraction take 
place i.e. actin filaments slide along the myosin filaments toward the H band and mid-line, M 
line. During the contraction, the I band and the H band are shortened while the length of the A 
band remains the same.107, 109  
 
 
Figure 6. An overview to the skeletal muscle cell illustrating the filamentous systems, 
interactions and connections between sarcolemma, sarcomere and nucleus (reproduced with 
permission from Dalakas et al. The New England Journal of Medicine 2000. Copyright © 






2.2.1 The Z disc 
Z discs, seen in EM (Fig 5B) as the darkest lines, define the border of the two adjacent 
sarcomeres, link sarcomeres to the sarcolemma, allow the force to be transmitted along a 
myofibril during contraction, and function in stretch sensing and signalling.98 
Z discs are composed of zigzag layers formed by the connections of the oppositely 
oriented thin (actin) filaments of the adjacent sarcomeres (Fig 5). The thickness, defined by 
the number of layers of the Z disc indicates different fibre types: in fast fibres it is ~30–50 nm 
and in slow and cardiac fibres ~100–140 nm thick. It has been proposed that the number 
and/or composition of the N-terminal domains of titin (the backbone of the third filament 
system) and the C-terminal domains of nebulin (the thin filament ruler) within a single 
sarcomere could differ and influence the thickness of the Z discs.110-112 
-actinin 2 belongs to the -actinin protein family. In muscle, it exists as a calcium-
insensitive protein forming the backbone of the Z disc, having the ability to bind many 
structural and signalling molecules.113-117 It is essential not only for mature muscle as a cross-
linker of multiple proteins, but together with titin it is needed for the proper assembly of the 
developing sarcomere, i.e. sarcomerogenesis.118 In mature muscle, actin and titin filaments 
are anchored together and cross-linked in the Z disc via -actinin 2.116 Other important Z-disc 
components include titin-binding and -capping telethonin,112, 119, 120 the capZ-complex, which 
binds to nebulin and caps the actin filament at the Z disc,112 as well as myotilin and 
myopalladin.114 In addition nebulin and titin are bound to each other in the Z disc.121 
2.2.2 The thin filament 
The backbone of the thin filament is an actin polymer (Fig 5). The lengths of the thin filament 
display some variability according to the fibre type and muscle tissue, though usually it is 
longer than 1 µm. Proteins bound to actin, determine the length of the thin filament and make 








Six different genes encode six actin proteins: -skeletal, -cardiac, -smooth muscle and -
enteric actin are tissue specific. In addition, - and -actins are expressed in almost all 
vertebrate cells where they act in maintaining the cell structure by forming an actin 
cytoskeleton.124 Actins are very conserved proteins, and do not seem to tolerate changes in 
the nucleotide and/or amino acid sequence. The gene encoding skeletal thin filament actin, 
ACTA1, is in chromosome 1. It has six exons and the length of the mRNA is 1374 bp. 
Two polymerised skeletal muscle -actin filaments coiled around each other form the 
backbone of the thin filament. Each globular actin molecule can bind to four other actins; two 
to the same and two to the second actin polymer of the same filament.125 In addition, actin 
has three binding sites for nebulin, and it binds troponin/tropomyosin complexes as well as 
several other proteins, which anchor the filament to the Z disc, and cap it in the H band 
(tropomodulin).126, 127 An -actin molecule contains Mg2+- or Ca2+-ions and ATP/ADP-binding 
sites, making energy-dependent muscle contraction possible due to the interaction with the 
myosin heavy chains of the thick filament.125 The structure of the actin polymer and filament is 
illustrated in Figures 5 (p. 26), 9 (p. 33) and 10 (p.35). 
2.2.2.2 Nebulin 
Nebulin is required for the proper assembly of the thin filaments and Z discs in mature muscle 
tissue as well as for defining and maintaining the correct lengths and contractile function in 
different fibre types.112, 128-131 Studies performed on nebulin fragments already over a decade 
ago, revealed that its domains periodically bind actin, calmodulin, tropomyosin and troponin 
complexes suggesting that the segmental structure of nebulin plays an important role in 
defining or maintaining the length of, as well as stabilizing the thin filament of the sarcomere.  
 
It has been estimated that there are two nebulin molecules spanning one thin 
filament.132 The ~20 kDa C-terminus of nebulin is anchored into the Z disc.133 It contains a 
conserved SH3 domain, which binds CapZ, titin and myopalladin. CapZ caps the Z disc end 
of the thin filament, titin forms the third filament, and myopalladin cross-links nebulin via -
actinin to the Z disc (among its other functions).112, 121, 134-138 The peripheral C-terminus binds 
desmin.139 Desmin is an intermediate-filament protein forming a bridge between the 
sarcolemma and the Z disc.140 The function of multiple phosphorylation sites seen in the C-
terminal nebulin is still not fully clarified.141 With respect to nebulin, 97 % (mainly in the I and A 





the 5.5 nm long simple repeats contains an actin-binding site (SDXXYK-motif). Depending on 
the isoform, nebulin may contain 179 – 239 simple repeats, each of which is capable of 
binding 179 – 239 actin monomers of the thin filament. Most of the simple repeats are 
arranged into super repeats, each seven simple repeats long with the potential to form 22 – 
30 super repeats (Fig 7). There is a WLKGIGW-motif present in every super repeat at 38.5 
nm intervals most probably for binding tropomyosin and troponin.122, 142 The binding of nebulin 
to the tropomyosin and troponin complex was deduced to form a calcium-linked regulatory 
complex.122, 129, 132, 133, 143 The 8 kDa N-terminus at the H band region contains unique 
domains for binding tropomodulin, which caps the pointed end of the thin filament.144-146  
 
 
Figure 7. A. The protein structure of nebulin and the binding-partners (tropomodulin (Tmod), 
desmin, CapZ, myopalladin and titin shown) of nebulin. M1-M8 and M163-M176 are simple 
repeats not organized into super repeats; S1R1-S1R7, S22R1-S22R7 are super repeats of 
seven simple repeats, Ser = serine rich and SH3 = Src homology domain. B. A detailed view 
of one nebulin super repeat (S1) consisting of seven simple repeats (R1-R7). The 
actin-binding motifs (SDXXYK) are present in the simple repeat boundaries and 
tropomyosin-binding motifs are present in the third simple repeat (R3) of every super repeat. 
(Adapted from The Sarcomere and Skeletal Muscle Disease, ed. Nigel Laing, with permission 
from Landes Bioscience and Springer Science) 
 
The calmodulin regulated interaction of nebulin with actomyosin suggests a role for 
nebulin in the regulation of muscle contraction via a calcium-linked system.143 It was shown 
that the N-terminus of nebulin inhibits the sliding of acting over myosin in in vitro mobility 
assays, while the C terminus located in the Z disc did not inhibit the sliding. The nebulin KO 
mice have provided new knowledge on the role of nebulin in vivo.112, 147 The results of two 
separate groups working with nebulin KO mice show that the animals which do not express 
nebulin do assemble sarcomeres prenatally, but the thin filaments are disorganized and 15 – 
25 % shorter than normal, and the Z discs are abnormally thick. The mice died at 
approximately two weeks of age resembling both clinically and histologically human patients 
with severe NM caused by mutations in NEB.112, 147, 148 It was hypothesised that in the muscle 






noted that the levels of the sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA) –inhibitor, 
sarcolipin (SLN), were upregulated in nebulin KO mice.112 As explained in Chapter 2.3, 
muscle contraction is triggered by the release of Ca2+ from the SR and relaxation occurs 
when Ca2+ is taken back up into to the SR by SERCA. Further investigations supported the 
hypothesis that nebulin has a role in handling Ca2+ in muscles and in regulating muscle 
contraction. The studies showed that if nebulin is not present in the muscle, SLN was up-
regulated, while the expression of other proteins involved in Ca2+ pathways were not 
significantly altered. In nebulin deficient muscle, the speed of Ca2+ uptake decreased and the 
relaxation time was significantly longer.131 
The gene encoding nebulin, NEB, (Fig 14, p. 55) is located to the chromosomal region 
2q22 and it is one of the biggest genes known,149 containing 183 exons in an area of 249 kb 
of genomic sequence. Translation begins at exon three and ends at exon 183. An 8.2 kb 
genomic region in the middle of the gene encompasses a triplication of a segment containing 
eight nearly identical exons (exons 82 – 89, 90 – 97, 98 – 105) and introns. These, as well as 
exons 63 – 66, 143 – 144 and 167 – 177, point to alternatively spliced exons theoretically 
giving rise to thousands of different nebulin isoforms. The splicing patterns of the triplicated 
area are not yet known in detail, but it has been predicted that the region may produce seven 
different length variants.150 Exons 63 – 66 form one cluster of exons which are either all 
included or excluded from the transcript (exon 62 is spliced to exon 67 or all exons 63 - 66 
included). Exons 143 and 144 are mutually exclusive, i.e. the transcripts always contain either 
of them, never both, while exons 167 – 177 are independently spliced, i.e. they are included 
or excluded independently of each other.151 The vast nebulin isoform diversity probably meets 
the different requirements of prenatal vs. adult muscle, different muscles and muscle fibre 
types.142, 152, 153 Due to its extensive splicing, the size of the nebulin protein varies between 
600 and 900 kDa.142, 151 Nebulin is mainly expressed in the striated muscle thin filament,122, 154 
but minor expression has been detected in the heart152 and possibly in the brain155. 
2.2.2.3 The tropomyosins 
Tropomyosins are -helical coiled-coil homo- or heterodimers which form a long filament by 
polymerising head-to-tail (Fig 8). The dimerised polymers run along the length of the actin 
molecule aside nebulin (Fig 9, p. 33 and 10, p. 35).157-160 Tropomyosins bind to actin, 
stabilising the thin filament, and together these molecules regulate muscle contraction.125, 127, 
161 A more detailed investigation of the tropomyosins reveals heptapeptide repeats (abcdefg) 
underlying the coiled coil structure. The a and d residues are generally non-polar and form the 








Figure 8. A. The coiled-coil structure of the dimerised tropomyosins. B. The heptad repeats 
(abcdefg) of  coiled coils; HPPHPPP where H are hydrophobic amino acids in the core of the 
helix, and P are polar exposed outwards from the molecule. One heptad is 2 nm in diameter 
and 1 nm long. C. Cross-section view of the coiled coils. (Reproduced with permission from 
Ryadnov MG, Biochem. Soc. Trans. 35, 487-491, 2007. Copyright © the Biochemical Society)  
 
Four different genes, all containing 10 exons encode the tropomyosins: TPM1, TPM2, 
TPM3, and TPM4. These genes can encode over 40 different tropomyosin isoforms due to 
alternative promoters and splicing.162-165 The genes TPM1, TPM2 and TPM3 encode the 
skeletal, exactly 284 amino acids long muscle-specific isoforms -tropomyosinfast, -
tropomyosin, and -tropomyosinslow. -tropomyosinfast (encoded by TPM1) is expressed in 
type II muscle fibres and is the most abundant isoform in the heart. -tropomyosin (encoded 
by TPM2) is present in both muscle fibre types; more abundantly in type I and less in type II 
muscle fibres (and in small amounts in heart). -tropomyosinslow (encoded by TPM3) is found 
in type I fibres only. When both - and -tropomyosins are expressed, -heterodimers are 
formed preferentially over -homodimers, and -homodimers are rare.127 
2.2.2.4 The troponin complex 
Troponin C (calcium binding), I (inhibitor) and T (tropomyosin binding) form a complex which 
regulates muscle contraction (Fig 8 and 9).125 There are several genes encoding troponins. 
Troponins I and T have specific isoforms for type I, type II and cardiac fibers (TNNI1, 2, and 3 
& TNNT1, 2 and 3), but troponin C has one gene encoding type I and cardiac fibre isoforms 
(TNNC1), and another gene encoding type II fibre isoform (TNNC2). These different isoforms 






2.2.2.5 The cofilins 
Cofilin 1, cofilin 2 (the skeletal muscle-specific isoform encoded by CFL2) and destrin belong 
to a protein family which regulate actin filament dynamics. In the thin filament, cofilin 2 acts 
together with the actin depolymerisation factor catalysing the depolymerisation of the actin 
filament.166 
2.2.3 The thick filament  
Myosin and myosin-binding proteins form the thick filament of the sarcomere (Fig 9). Myosin 
is the main component, but hundreds of other components contribute to the actin-myosin 




Figure 9. Thin and thick 
filament structures and 
interaction. Head, neck and 
tail domains of the myosin 
molecule pointed out. 
(Reproduced and modified 
with permission from Spirito 
et. al. The New England 
Journal of Medicine 1997. 




Myosins form a protein family of molecules able to bind actins and hydrolyse MgATP for 
energy, for example for cell crawling. Myosins consist of two identical heavy (MyHC) chains 
and two different pairs of light chains (MYL), and there are three domains in the myosin 
molecule: Head, neck and tail. MyHCs are divided into classes I and II, with the seven 
isoforms expressed in vertebrate skeletal muscle belonging to class II. Myosins are encoded 
by a total of ~40 genes belonging to ~12 classes according to their head and tail domain 
structures.168 The various MyHC isoforms in different muscle fibre types bind actin with the 






which act as a regulatory platform, and the tail maintains the structure of the molecule and 
provides the anchoring point. In the sarcomere, myosin molecules exist as a chain of 147 
myosin molecules. The myosin chains of the opposite thick filaments are bound together by 
M-band proteins such as myomesin, and 294 myosin molecules form an exactly 1.59 µm long 
and 1 nm thick filament. Another protein worth mentioning is myosin-binding protein C, which 
enables the muscle to regulate its contraction (Fig 9).168-170 
2.2.4 The third filament - titin 
While nebulin defines the length of the thin filament, titin (Fig 5A, p.26) is the ruler of the 
whole sarcomere. Titin, 3600 kDa in size, forms the backbone of the third filament of the 
sarcomere. It provides the elastic stabilising spring which spans the distance from the Z disc 
to the M line, i.e. a titin filament spans half of the sarcomere, and binds and interacts with 
several proteins along its length. It consists of several domains with different functions 
needed in different parts of the sarcomere.171-174 About 100 kDa of  the N-terminus of titin is 
bound to the Z disc, being cross-linked to it via several proteins, such as calpain 3 and -
actinin.119, 120, 175 A 1500 kDa section of the I-band titin includes the calpain 3-binding N2A-
region and functions as an elastic spring which is able to shorten during contraction in relation 
to the shortening of the whole I-band.174, 176 In the A-band, 1750 kDa of titin is cross-linked to 
the myosin filament which in turn is linked to actin by myosin-binding protein C.177 During 
contraction, the length of the A-band remains stable.108 
The more complex 250 kDa M-line part of titin serves as a signalling platform for 
several pathways which function in the coordination of the sarcomere. This region of titin 
interacts with myomesin and contains sequences of several signalling domains such as the 
kinase domain. The kinase domain, in turn, is a binding region for several signalling 
complexes, which e.g. provide a mechanical sensor for muscle contraction activity. The 
muscle sarcomere can react to external stimuli according to the binding state of the signalling 
molecules present in these titin M-line bound complexes. For example, if a signalling molecule 
is bound to titin, it is inactive – if unbound it shuttles to the nucleus and regulates the 
transcription of other muscle genes via SRF (the serum response factor).178 In the M-line, the 
two titin molecules of the opposite halves of the sarcomeres are bound together.179 Among 
other functional roles of titin, it has a role in stabilizing and activating calpain 3. Calpains are 
calcium-dependent intracellular proteases of which calpain 3 is the most abundant isoform in 
skeletal muscle. In the sarcomere, titin-bound calpain 3 is believed to act as a sarcomeric 






The protein is encoded by the gene TTN  which contains 336 exons and the whole 
gene covers 294 kb of genomic DNA in chromosomal region 2q31. The gene is extensively 
spliced to meet the requirements of different muscle fibre types and in different phases of the 
maturation of the muscle cell. It is also one of the first genes expressed during 
sarcomerogenesis and seems to be essential for this process.177, 181-184  
2.3 Muscle contraction 
Due to the complex cascades evoked by the action potential of the motor neuron, the 
sarcolemma of the muscle fibre is depolarized, which in turn triggers a reaction elevating the 
calcium level within the muscle cell. Calcium binds to troponin C, which causes 
conformational changes of the complex, and the movement of tropomyosin to expose myosin-
binding sites on the actin filament (Fig 10). Myosin can now tightly bind to actin (Fig 9, p. 33 
and 10). the subsequent reactions release ADP and inorganic phosphate from myosin to 
generate the force needed for the myosin head domains to drag the thick filament along the 
thin filament i.e. pulling the Z-discs closer to each other. Next, ATP is bound to myosin which 
detaches from the actin, and then ATP is hydrolysed to ADP and the myosin is ready to 
interact with actin again. This continues until no calcium or ATP is left, and the troponin-
tropomyosin complex changes its conformation back to the resting state. In resting muscle, 





Figure 10.  
The principle of the 
interaction of the thin 
filament and Ca2+ 
during muscle 
contraction.  
Nebulin runs along 
the tropomyosin 
dimer. (Figure
provided by Professor 
David Warshaw, 






3 Nemaline myopathy and related disorders of the muscle 
sarcomere 
Is has been estimated that there are at least 1000 muscle-specific genes in the human 
genome. If an error occurs in any of these genes, the likely outcome is a muscle disorder. 
Most often mutations causing muscle disorders interfere with muscle cell structure, 
contraction and/or energy metabolism.101-105 
Neuromuscular disorders constitute a wide spectrum of diseases characterised by 
muscle weakness and hypotonia. The primary defect may lie in the anterior horn cell of the 
spinal cord, in the nerve innervating the muscle, in the neuromuscular junction or in the 
muscle cell itself. Generally speaking, the primary defect causing muscle weakness in 
myopathies lies in the muscle itself, while the defect causing muscle weakness in 
neuropathies is located in the nerve. The weakness and the muscles affected vary between 
different disorders and even between individuals with the same disease. Usually these 
disorders are painless, or pain is not the predominant symptom. The disorder can affect some 
muscle groups specifically (e.g. proximal or distal) or even some specific muscles only. 
Neuromuscular disorders have been classified on the basis of clinical and histological criteria 
into several different groups and sub-groups (e.g. Dystrophies; Duchenne muscular 
dystrophy (DMD), Myotonic dystrophy etc), which often in turn are divided according to 
additional criteria, for example the degree of severity and underlying genetic defect. This 
thesis concentrates on the molecular genetics of some of the congenital (inborn) myopathies 
(Greek: myo = muscle, pathy = suffering/disease), in particular muscle disorders caused by 
mutations in genes encoding proteins for the muscle sarcomere.107, 186 The disorders in focus 
are nemaline myopathy,187, 188 distal nebulin myopathy (II) and cap myopathy189. 
Congenital myopathies are neuromuscular disorders which include clinically, 
histologically and genetically variable disorders defined on the basis of microscopic structural 
abnormalities in the muscle fibres.190, 196 They may be caused by mutations in one or several 
possible genes. The symptoms are not directly correlated with the histological characteristics. 
In the congenital myopathies, the muscle tissue does not show any signs of inflammation or 
progressive muscle fibre death (necrosis).43 
In this chapter, the most relevant disorders and entities for this thesis are briefly 
presented. Although in this project disorders of the thin filament were studied, some disorders 
of the thick and the third filament, which are interesting from the point of view of the thesis, 






3.1 Thin filament disorders 
Dysfunction of the structural or functional proteins of the thin filament is seen in a variety of 
muscle disorders, most of them shown to be attributable to mutations in the genes encoding 
these proteins. In addition, mutations in the same gene may cause several different disorders, 
while mutations in different genes can cause a very similar clinical outcome. For example, 
mutations in ACTA1, NEB, TPM2, and TPM3 are all known to cause nemaline myopathy 
(NM), but can also cause a variety of different and overlapping disorders.191 Of these, 
nemaline and cap myopathy are included here. 
3.1.1 Nemaline myopathy (NM) 
Nemaline (rod) myopathy is one of the most common forms of congenital myopathy. It was 
first described in 1963 with its characteristic protein aggregates, called nemaline bodies, seen 
with LM in Gomori trichrome-stained muscle fibres.187 NM was, however, perhaps first seen 
by Dr. Reye 1958 in a patient in whom a mutation in ACTA1 was later identified.192 The 
weakness of NM patients is usually non-progressive or slowly progressive and proximal 
muscles are typically more severely affected than the distal counterparts, but the distribution 
of the affected muscles as well as the severity of NM varies enormously between patients.193-
196 The occurrence of NM is difficult to estimate reliably, but it is very rare. The incidence in 
Finland has been estimated to be 0.02 per 1000 live births.197 Based on the clinical variability 
of NM, it is divided into six subclasses: severe, intermediate, and typical congenital forms of 
NM, and mild childhood or juvenile onset, adult onset NM and other forms.193 The disease 
can be inherited as an AD or as an AR trait, and new dominant mutations are also quite 
common.198-200 Nemaline body-like aggregates can be seen in other disorders, e.g. in the 
muscles of AIDS patients.201 
3.1.1.1 Classification of NM 
The European Neuromuscular Centre International Consortium on NM has categorised NM 
into six clinical classes:202 The severe form of NM (Fig 11A and B) is often noticed even 
before birth due to the immobility of the foetus, or immediately after birth due to respiratory 
problems, severe muscle weakness, hypotonia and lack of spontaneous movements, 
difficulties in suckling and swallowing, and in some patients contractures and occasionally 






NM die soon after birth because of general severe muscle weakness and respiratory 
insufficiency. The intermediate form of NM is intermediate in severity between the severe 
and typical form. Muscle weakness is evident at birth, but spontaneous movements are 
present, and there are no major contractures or fractures. The child may never be able to sit 
unassisted or walk and possibly needs a wheelchair before the age of eleven. Typical NM 
(Fig 11C and D) is often evident at birth. The newborn is floppy and weak, but spontaneous 
movement and respiratory  efforts are present. Feeding problems are common. There are no 
contractures or fractures. The most severely affected muscles are usually the facial, neck and 
proximal muscles of the limbs and axial muscles of the body. Later the distal muscles may 
become affected as well. The patients often have an expressionless face and a nasal voice 
due to the affected facial and bulbar muscles. These children achieve their motor milestones 
later than healthy children, and some need to move in a wheelchair in their teens. Patients 
with typical NM usually live rather normal lives despite their muscle weakness, but they may 
experience severe breathing problems. In mild childhood or juvenile onset NM, the onset is 
later, the muscle weakness milder and the facial muscles may not be involved. In adult onset 
NM, the patients can display a variety of symptoms. This form of NM might not have a genetic 
background at all. The patients belong to the group of other forms of NM if they, in addition 
to diagnosed NM, have for example cardiomyopathy, ophthalmoplegia, or other unusual 
clinical symptoms or histological findings, for example, intranuclear nemaline bodies observed 
in the muscle biopsy.203 Sometimes the form of NM is difficult to define due to the overlap 
between different forms NM and symptoms of individuals.193, 202 
3.1.1.2 Molecular genetics of NM 
Mutations underlying NM have been identified in six genes which encode thin filament 
proteins of the sarcomere. These are the nebulin (NEB),199 -actin (ACTA1),200 -
tropomyosinslow (TPM3),
198 troponin T1 (TNNT1),204 -tropomyosin (TPM2)205 and cofilin 2 
(CFL2)206 genes. According to candidate gene and genome-wide linkage analyses, it can be 
assumed that at least a seventh NM gene is still to be identified.206 
NM-causing NEB mutations had been published, prior to the current study, in 
approximately 20 NM probands, causing all forms except for the adult-onset form of NM. The 
most common form of NM caused by NEB is the typical form.194, 199, 207 All the mutations 
identified are AR and ~90 % compound heterozygous, and most often both of the mutations 
are unique to the family.199, 207, 208 In addition, a founder mutation, a deletion encompassing 






Mutations in ACTA1 are thought to be responsible for 20 % of congenital 
myopathies.209, 210 Most of the over 140 mutations identified in ACTA1 cause NM.210 
Mutations in ACTA1 can, however, cause a variety of other disorders as well: actin myopathy 
(patients have aggregates consisting of actin in their muscle fibres),200, 211 intranuclear rod 
myopathy,210, 212 congenital fibre type disproportion (without rods) (CFTD) and myopathy with 
core-like lesions (Fig 12)195, 213  De novo dominant mutations are the most common cause in 
severe, even lethal, forms of NM, but ACTA1 mutations can also be recessive or inherited in 
a dominant fashion, and underlie mild forms of NM.194, 200, 210, 214, 215 Somatic mosaicism has 
been seen in two families with mildly affected parents and severely affected children.216 
NM-causing mutations in the -tropomyosin gene, TPM2, were first identified in 
2002 in two families. One of the mutations was a likely de novo AD mutation causing NM and 
another was an AD mutation identified in an affected mother and her affected son leading to 
CFTD.205, 217 A dominant mutation said to cause distal arthrogryposis (multiple congenital 
contractures of the joints) type 1 (DA1) was identified soon after this, in 2003.218 Mutations in 
TPM2 are known to cause other entities as well.219 These will be discussed further in the 
section “Results and Discussion”. 
Mutations in the gene for -tropomyosin slow, TPM3, have been identified in both 
recessive and dominant forms of NM and in CFTD.198, 219-221, 260, 263 These will be discussed 
further in “Results and Discussion”. 
Only one mutation, a founder mutation of the Old Order Amish population, has been 
identified in the troponin T1 gene TNNT1. The mutation detected is a nonsense mutation in 
exon 11 of the gene in homozygous form causing progressive, severe NM which typically 
leads to the death of the patient during the second year of life. The incidence of the disorder 
among the Old Order Amish is approximately 1:500.204 One AR mutation has been identified 
in the gene encoding cofilin-2, CFL2, in one sib pair from a large family of Middle Eastern 
origin. The mutation is a missense mutation A35T and in its homozygous form it caused a 
clinical picture resembling the typical form of NM, although no foot drop or weakness of the 
facial muscles was observed in these patients. The biopsies of the patients displayed 








Figure 11. A. Typical NM caused by mutation of NEB. B. Typical NM caused by mutation of 
ACTA1. C. Severe NM caused by mutation of NEB. D. Severe NM caused by mutation of 






3.1.1.3 Histology of NM 
Histological features mentioned in this chapter are nemaline bodies (rods), fibre type 
disporotion (CFTD) and cores: Nemaline (rod) bodies, (Fig 12A) are protein aggregates best 
seen in the cross-sections of Gomori trichrome-stained muscle fibres. They usually arise from 
the Z discs, but may in some cases be intranuclear. In CFTD (Fig 12B) describes the situation 
in which the type I fibres are smaller than type II fibre sizes 220, 223 Central cores or cores 
(Fig 12C) are compact regions or zones seen in the centres of cross-sections of myopathic 
fibres and, being devoid of mitochondria, they are easily identified in oxidative enzyme 
reactions. In longitudinal section the cores run along the length of the fibre (Fig 12C2). 
Minicores are smaller than (central) cores in both in cross-section and in longitudinal 
sections.99  
 
Figure 12. A. Rods R = rod 1. Nemaline rods / bodies (dots pointed by arrows) in Gomori 
trichrome-stained in cross-section of muscle fibres (LM), 2. in longitudinal section of muscle 
fibre (EM), 3. intranuclear rod: N = nucleus, (EM). B. CFTD: small type I fibres appear dark in 
ATPase (pH 4.3) stained cross-section. Type II fibres appear pale. (LM), C. central core 
structures: 1. in longitudinal section (LM), 2. in cross section (LM) 3. in longitudinal section 
(EM). (Figures kindly provided by Professor Kathryn North and Dr. Nigel Clarke, University of 
Sydney, Australia, Professor Norma Romero, Groupe Hospitalier Pitié-Salpêtrière, Paris, 
France and Professor Caroline Sewry, Imperial College, London, UK ) LM = light microscope, 







The nemaline bodies are the defining characteristic of NM. Nemaline bodies (Fig 12A) are 
protein aggregates containing -actinin, -actin and other Z-disc and thin-filament proteins. 
The nemaline rods have no enzyme activity. They usually accumulate under the sarcolemma, 
but they may be centrally located as well.187, 196, 222 If one is using the light microscope (LM), 
the best method to identify nemaline bodies (rods) is the modified Gomori trichrome stain, 
where the bodies appear as very dense dark red rods against a turquoise background (Fig 
12A1). Gomori's trichrome staining procedure combines a plasma stain and a connective fibre 
stain. Hematoxylin and eosin (HE) stained nemaline bodies may appear as non-specific pink 
bodies. It can be said that in the HE section, hematoxylin stains nucleic acids and other 
basophilic structures purple-bluish, whereas eosin stains protein-rich eosinophilic structures 
such as cytoplasm red-pink.99 Viewed using the EM (Fig 12A2), the smaller nemaline bodies 
appear as thickened disorganised Z discs but larger bodies are not clearly connected to the Z 
discs. Nemaline rods are osmiophilic. Osmium tretroxide is used to enhance contrast in the 
EM; the rods appear darker when they bind osmium. 
Both or one of the type II muscle fibre types are usually deficient in NM, and the type I 
fibres tend to be small, in many cases fulfilling the mathematical definition of CFTD (i.e. the 
difference between type I and type II fibre sizes should be at least 12 %)220, 223 (Fig 12B). 
CFTD may be considered a disorder per se, if no rods or other specific structural 
abnormalities are present in the biopsy.221 Nemaline bodies are mostly seen in type I fibres, 
especially in childhood cases, but they can also be seen in type II fibres.202 The proportion of 
the affected fibres in situ may vary greatly between different muscles and even within the 
same biopsy, and may change with age. Fibres containing nemaline bodies are often quite 
atrophic (wasted) or hypotrophic (decreased in size), but both atrophic and hypertrophic 
(increased in size) fibres may be affected. Muscle biopsies of patients with NM can, in 
addition, show overlapping histology with central core (Fig 12C) / core-rod disease, and other 
related entities, complicating the histological definition of NM in some cases. Clinically the 
patients affected with the entities mentioned may be very similar to NM patients. Usually 
these patients with additional histological features are classified into the category of “other 
forms” of NM.196 Nuclear rods (Fig 12A3) and cardiac nemaline bodies can rarely be seen and 
they tend to correspond with more severe forms of NM. The quantity of nemaline bodies does 






3.1.2 Cap myopathy 
“Cap myopathy”, also known as “cap disease” is a congenital myopathy first described in 
1981 by Fidzianska and colleagues in a seven-year-old boy who was examined for non-
progressive muscle weakness, hypotonia, skeletal dysmorphism and respiratory insufficiency. 
The boy died at the age of eight years because of respiratory complications.189 Subsequently 
after reporting the first case of Fidzianska’s, she has reported three additional cases. All the 
patients had childhood onset but clinically variable cap myopathy.227 In addition, in 1992 
Gibbels reported a case with possible cap myopathy or an unusual form of NM228 and in 1996 
Martland presented a cap myopathy sib pair.229 In total, the cases published to date include 
15 cap myopathy patients in 13 families. 
The more recent descriptions of cap myopathy patients show that this entity can vary 
clinically and histologically and may overlap with NM. The cases are often sporadic but there 
are familial cases showing AR or AD inheritance. Marked differences in severity and 
distribution of the muscle weakness have been observed between different individuals, but 
the facial and the neck muscles are affected in the majority of patients.230-233 In some families, 
certain affected family members have NM or an undefined muscle disorder, while others are 
diagnosed as having cap myopathy.228, 230, 232 The molecular genetic aspects of cap myopathy 
are discussed under “Results and Discussion”. 
3.1.2.1 Histology of cap myopathy 
The disorder is identified on the basis of the cap-like structural abnormalities lacking ATPase 
activity on one side of the cell/fibre under the sarcolemma (the muscle cell membrane) (Fig 
13, p. 45). These caps have been revealed to be massive protein aggregates consisting of 
disarranged thin filaments with enlarged Z discs, while myosin filaments seem to be absent, 
and in the trichrome stain, “cap” structures exhibit a granular appearance.189, 227, 234 The caps 
are often positively labelled with antibodies against desmin, -actinin, -actin and 
tropomyosin, and have been shown to be negative for adult isoforms of myosin.227, 232, 233 
In cap myopathy patients, type I fibres are often hypotrophic and type I 
uniformity/predominance is common.189, 227-233 The histological findings may vary even in 
biopsies of the same person taken at different time points and/or from different parts of the 
body.228, 230, 232 It has been postulated that the severity of the disorder may correlate with the 















1 At birth; progressive, death at 8 
yrs from respiratory failure 
7 yrs Caps in 70-75 % of fibres 
2 At birth; progressive, death at 
14 yrs 
12 yrs Caps in 70-75 % of fibres 
3 Childhood; slowly progressive 18 yrs 
21 yrs 
Caps in 20-30 % of fibres 
Caps in 20-30 % of fibres 





Slight improvement of muscle 
strength reported at age 7  
20 months 
7 yrs  
Caps in 13 % of fibres 
Rods in 1 % of fibres, caps 






Neonatal; slowly progressive. 
Ambulant at 15 yrs. 
Infantile; slowly progressive. 
Ambulant at 33 yrs.   
Neonatal; severe NM, death at 







Caps in 40 % of fibres 
Normal 
Caps in 20 % of fibres 
Nemaline bodies in 60 % of 
fibres 






A brother with similar 
symptoms. 
13 yrs Caps  











2,5 yrs  
26 yrs 
32 yrs  
57 yrs  
No aggregates  
Caps 
No aggregates  
nemaline bodies    
11 Infantile; slowly progressive. At 
42 yrs, uses a wheelchair 
outdoors.   
15 yrs 
 
30 yrs  
No aggregates 
 
Caps in 15 % of fibres 
12 Infantile; slow improvement  3 yrs No aggregates seen using 
LM, but in EM small caps. 
13 Neonatal; non-progressive  5 yrs Caps 
S = sibling, H.C.= half cousin, D = daughter, M = mother, cons. = consanguineous1-4:189, 2275:228 








Figure 13. Cap structures consist of disorganised thin filaments and usually locate on one 
side of the cell/fibre under the sarcolemma (the muscle cell membrane). A. LM, B. EM 
3.2 Thick filament disorders 
Thick filament myopathies include a group of disorders called hereditary myosin myopathies. 
Mutations in any of the genes encoding myosin heavy or light chain proteins could potentially 
underlie a thick filament myopathy. To date, mutations have been identified in the genes for 
two embryonic isoform (MYH3 and MYH8) and two adult isoform myosin heavy chain genes 
(MYH2 and MYH7). These mutations cause a wide range of disorders from arthrogryposis to 
distal myopathies, progressive muscle weakness as well as cardiomyopathies or 
ophthalmoplegia, i.e. paralysis of the extraocular muscles. At present, no mutations have 
hitherto been identified in myosin light chain genes.235, 236 
3.2.1 Laing distal myopathy and other MYH7-related disorders 
MYH7 (in chromosomal region 14q12) encodes the -cardiac and type I muscle fibre-specific 
myosins.235 Most, over 200, mutations in MYH7 cause cardiac myopathies without any 
skeletal muscle weakness.236 Some, however, underlie Laing distal myopathy (LDM).237 LDM 
is usually a childhood onset distal myopathy (although a few adult-onset cases have been 
reported) typically first diagnosed due to weakness of the toes (“hanging toe”) and ankle 
dorsiflexors. This usually slowly progressive disorder next affects finger extensors and neck 
flexors, and finally the weakness spreads to the upper muscles of the limbs and the facial 
muscles. In most cases patients retain their ability to walk till the fifth decade of life.237, 238 Two 
patients have been reported to have both LDM and cardiomyopathy.239, 240 No specific 






variation in fibre size, central nuclei and streaming of the Z discs.241 Most of the mutations 
causing LDM have been identified in the tail region of MYH7, in exons 32, 34, 55 and 36. 
These exons encode the light meromyosin region of the protein.238 Recent mutations, 
however, in patients with LDM with cardiomyopathy have been located in exons 14 and 16 
encoding the globular head of MYH7.239, 240 The mechanisms by which the mutations cause 
the disorder were first believed to be due to interrupted coiled-coil structure of the protein, but 
the discovery of the mutations in exons 14 and 16 indicate that disrupted binding to titin, 
myomesin or M-protein may play important roles in the pathogenesis of LDM.236  
In addition to LDM, mutations in MYH7 may cause myosin storage myopathy in which 
all mutations identified to date are located close to the assembly competence domain 
(functioning in the polymerisation of the molecule) of the protein in the distal rod region of the 
myosin heavy chain. It is believed that this situation prevents myosin dimers from assembling 
into the thick filaments.242, 243 
3.3 Third filament disorders 
The backbone of the third filament is titin encoded by TTN. In addition to mutations in TTN, 
mutations in calpain 3, myotilin and telethonin are known causes of a variety of third filament 
diseases, such as the limb girdle muscular dystrophies (LGMDs) (a group of disorders 
predominantly affecting the pelvic and shoulder girdles),244-246 cardiomyopathies,247, 248 tibial 
muscular dystrophy (TMD),249, 250 and hereditary myopathy with early respiratory failure.178, 251 
The first mutation in a third filament protein-encoding gene, calpain 3, was identified in a 
LGMD2A-patient in 1995. To date some 300 mutations have been found in this gene.244, 252 
3.3.1 Tibial muscular dystrophy and LGMD2J 
Tibial muscular dystrophy (TMD) is an adult-onset muscular disorder. Typically the onset is 
after the mid-forties and the disease specifically affects the anterior tibial muscles, weakening 
the dorsiflexion of the ankles, and later the long toe extensors. The muscle biopsy displays 
variability in fibre size and central nuclei. During the later course of TMD, fibrosis and fatty 
replacement become evident. The sarcomere structure does not seem to be disturbed.249 
TMD is an AD disease caused by heterozygous mutations of the M-line titin region. To date, 
six TMD-causing TTN mutations have been identified.250, 253, 254 Recent studies suggest that 






While one of the Finnish founder mutations (an in-frame deletion-insertion of 11 
nucleotides in the last exon, exon 363, of TTN 250) in heterozygous form is known to cause 
TMD, in the homozygous state, it causes a more severe muscle disorder, LGMD2J. In this 
disorder, the homozygous TTN mutation leads to loss of ambulation by the age of 25 years 









The aims of this study were to: 
 
1.  Optimise the mutation screening of NEB using denaturing High Performance 
Liquid Chromatography (dHPLC).  
 
2. Estimate the occurrence in an international sample collection of the deletion of 2 
502 bp including NEB exon 55 identified in the Ashkenazi Jewish population by 
Anderson and colleagues (2004).  
 
3.  Identify novel mutations in NEB using dHPLC and to discern any emerging 
genotype-phenotype correlations. 
 
4.  Detect either a novel NM gene or a founder mutation in a known NM gene in 
consanguineous Turkish patients using linkage analysis and sequencing of 
candidate genes.  
 







Materials and methods 
1 Families and control individuals 
A total of some 300 families were included in this study. The families were from a variety of 
countries and of various ethnic origins. The research project has been approved by the Ethics 
Committee for Pediatrics, Adolescent Medicine and Psychiatry of the Helsinki University 
Central Hospital. The patients or their guardians have given their consent for having their 
samples and data included in the study. Control DNA samples were provided by Centre 
d´Etude du Polymorphisme Humain (CEPH) and the Finnish Red Cross Blood Transfusion 
Service. All control individuals were anonymous. 
1.1 Families included in the dHPLC analysis (I) 
Patients and families were selected on the basis of linkage results and/or the clinical and 
histological picture of the patient. All families selected for NEB mutation analysis had likely 
AR NM and mutations in ACTA1 had previously been excluded by sequencing (personal 
communication with Prof. Nigel Laing). In familial and/or consanguineous families, TPM2, 
TPM3 and TNNT1 had been excluded by sequencing or linkage analyses as part of this study 
or in previous projects. The first analysis batch (I) included samples from 45 NM patients 
and/or their parents. All known Finnish NM families were included. Samples from 42 patients 
or their families were included in the second dHPLC series, when the dHPLC analyses were 
further optimised and each PCR-fragment was run at two or three analysis temperatures 
(unpublished).  
1.2 Screening for the deletion of exon 55 (II) 
In total, 208 probands in our cohort, i.e. all the NM probands with no previous genetic cause 
identified or with the second of the NEB mutations unidentified. As part of this project, results 
of our collaborators in Perth, Australia, and Boston, USA, were collected and summarised. In 







1.3 Identification of distal nebulin myopathy (III) 
Two of the four Finnish families with the distal nebulin myopathy described in this study were 
first selected for another ongoing study, and due to their geographic origin, their DNA 
samples were used as ontrols in the haplotype analyses performed using SSCP. Altogether, 
in this study, 12 Finnish and 12 families from other countries  were included. 
1.4 Families included in candidate gene analyses (IV) 
As part of this study, some 300 families were classified for analyses according to their clinical 
and histological data (the form of NM or other entity, the mode of inheritance, ethnic origin, 
and any useful clinical or histological clues). On the basis of this classification, linkage studies 
and/or direct sequencing of possible candidate genes were performed. In total, six known NM 
and 20 candidate genes were analysed either by haplotyping or by sequencing (Table 2).  
1.5 Families included in the genome-wide linkage analysis (V) 
In order to identify the seventh NM gene and/or a founder mutation in a known NM gene 
causing NM in the Turkish population, 12 Turkish families were included in the study; ten 
consanguineous and two non-consanguineous multiplex families.  
2 Methods  
2.1 Summary of the common methods used  
DNA isolation and purification        I –V 
Saliva: OrageneTM saliva kits (DNA Genotek Inc., Ottawa, Canada) 
Blood, fibroblasts of cultured skin biopsies or myoblasts cultured from muscle biopsies: 
Genomic 
DNA Purification Kit (Gentra Systems, Minneapolis, USA) 
RNA isolation and purification       I, III-V 








Whole-genome amplification        I, III-V 
Phi29-DNA-polymerase / Illustra GenomiPhi DNA Amplification Kit (GE Healthcare, Chalfont 
St. Giles, UK)  
PCR and RT-PCR          I, III-V 
Basic procedures used and described in the articles 
Sequencing          I, III-V 
Sequencing performed using an ABI 3730 DNA Analyzer (Applied Biosystems, Fosters City, 
USA) 
Sequence analysis programmes used:  
 BioEdit (Ibis Biosciences, Carlsbad, USA) 
 Sequencher 4.1. (Gene Codes corporation, Ann Arbor, USA) programmes.  
If a myoblast cell culture or a muscle biopsy was available, RT-PCR was performed and the 
patient’s NEB cDNA sequenced. 
Analysis of the deletion of the whole exon 55      II 
As described by Anderson and colleagues.208 
Cloning and minigene method        I 
Described in details in the article     
2.2 Genotyping, creating haplotypes and linkage analysis (I – V)  
Genotyping: SNPs were used when analysing known NM-causing genes, and microsatellite 
markers when analysing candidate genes. SNP analysis was performed by SSCP or 
sequencing. The SNPs were chosen on the basis of data gained from the previous studies 
and from the SNP consortium database. The genotypes are available at 
http://www.ceph/fr/cephdb. Using fluorescently labelled primers, microsatellite markers were 
analysed using GeneMapper version 5.0 (Applied Biosystems, Foster City, USA). Markers 
closest to the gene were selected using the NCBI MapViewer 
(http://www.ncbi.nlm.nih.gov/mapview/). The genome-wide analysis was performed at the 
Finnish Genome Centre, Biomedicum Helsinki, using a 10 cM map of microsatellite markers. 
Haplotyping: In the candidate gene analyses, haplotypes were created manually for all 
members available of the multiplex and/or consanguineous families. If no other family 
members were available for the analysis, the sample of the affected member alone of the 
consanguineous families was included. The Finnish Genome Centre provided the haplotypes 
of the genome-wide scan. Linkage analysis: The pair-wise linkage analysis was performed 






2.3 dHPLC analysis (I) 
For NEB analysis, primers were designed to 159 of the 183 NEB exons (the 8 exon 
triplication in the middle of NEB was excluded from the dHPLC analysis) covering one or two 
exons per PCR reaction. According to the melting temperatures of each PCR fragment, 
unique analysis conditions were designed (running temperature, acetonitrile/TEAA buffer 
gradient etc) for each fragment using the software of dHPLC provided by Wave 
Transgenomic Ltd (Transgenomic, Omaha, USA). Chromatograms were analysed manually 
comparing the result of each individual chromatogram peak to the other peaks in the analysis 
plate exon by exon. Samples showing an abnormal chromatogram peak were sequenced for 
a possible mutation. 
2.4 Web-based tools used (I, III-V) 
Primer design: 
Primer3 (versions 0.3.0 and 0.4.0) (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi 
Analysis tools to predict the effects of the possible mutations: 
 Sequence comparison tools NCBI-BLAST at http://blast.ncbi.nlm.nih.gov/Blast.cgi 
 Analysis of ESE factors using ESEfinder 2.0 at http://rulai.cshl.edu/tools/ESE2/ 
 Coiled coil analysis tool COILS at 
http://www.ch.embnet.org/software/coils/COILS_doc.html 
 Phosphorylation site search NetPhos 2.0 at http://www.cbs.dtu.dk/services/NetPhos/ 
 Interspersed repeats of DNA sequences RepeatMasker at 
http://www.repeatmasker.org/ 







Table 2. The known NM genes and candidate genes analysed by haplotyping and/or 
sequencing (and/or in the case of NEB analysed using dHPLC) in this study (known NM 
genes in bold). The numbers indicate the number of families and/or probands analysed for the 
given gene. 
 
GENE (CHR. LOCATION)                HAPLOTYPED SEQUENCED 
 
ACTA1 (1q42.13)    41 
CFL2 (14q12)               20 
NEB (2q22)     95          97 (seq or dHPLC) 
TNNT1 (19q13.4)    25                   4 
TPM2 (9p13.2-1)    18         40 
TPM3 (1q21.2)    39        45 
ACTN2 (1q42-43)    8 
ACTN3 (1q13.1)    3 
CAPZA1 (1p13.2)               6 
CAPZA2 (7q31.2-3)                         6 
CAPZB (1p36.1)                5 
DES (2q35)     19                               4 
FLNC (7q32-35)    11 
LMNA (1q21.2-3)                6 
MYO (5q31)    29 
MYPN (10q21.3)    8  
NEBL (10p12)    2 
OBSCN (1q42.13)    6 
RYR1(19q13.1)    41 
SEPN1 (1p36.13)    19                    24 
TCAP (17q12)    4 
TPM1 (15q22.1)    2 
TTN (2q31)     7 
YL1+TMOD4 (1q12)    20            19 






Results and discussion 
1 Mutation analyses of NEB (I - III) 
Using dHPLC, RT-PCR and direct sequencing, 115 NEB mutations had been identified in 96 
families by March 2009 (Fig 14, Table 3): the typical form of NM was diagnosed in 44 % of 
cases, severe in 25 %, mild in 9 %, intermediate in 5 %, other/unusual forms of NM in 3 %, 
and 9 % of the analysed probands had not been classified because of insufficient data (I and 
unpublished results). Distal nebulin myopathy (DNM) was diagnosed in four (III) and core-rod 
myopathy in one family (Romero&Lehtokari et al., accepted in Neurology) (5 %). Mutations in 
NEB have not hitherto been identified in patients with adult onset NM. All the mutations 
identified to date are summarised and discussed here in order to have all available data 
included and provide a broader view on the phenotypes caused by these mutations. NM-
causing mutations, i.e. 92 % of the NEB mutations identified, are compound heterozygous 
and most often both of the mutations are unique to the family. Mutations are found along the 
whole length of the gene and no true mutational hotspots or recurrent mutations are evident. 
In this genomic area of 249 kb, the occurrence of different kinds of mutations seems to be 
rather equal (point mutations vs deletions/insertions). Point mutations account for 59 % of all 
the NEB mutations (missense 14 %, nonsense 17 % and splice-site 28 % of mutations). 
Small deletions, duplications or insertions (38 %), leading to either frameshifts (all except one 
in-frame deletion) and subsequent premature termination codons, or to disturbed splice 
signals (2 %) account for 39 % of the mutations identified. A 2,502 bp deletion erasing the 
whole exon 55 identified in the Ashkenazi Jewish population208 accounts as a single mutation 
for approximately 1 % of the mutations. This mutation was analysed in a total of 355 
probands (of the sample cohorts of Helsinki, Boston and Perth) and found in 14 of these. This 
is 2 % of all 702 NM probands from which these three main NM research centres had DNA 
samples. All the patients carrying the deletion shared the same haplotype and thus the 
mutation was shown to be a founder mutation (II). If the mutations are organised according to 
their predicted or known effect on the RNA or protein, truncating (nonsense and frameshift) 
mutations account for 54 %, splice-site mutations for 30 % and missense mutations for 14 % 
of all identified NEB mutations. The majority of the splice-site mutations skip one exon from 
the transcripts (in-frame exon skipping). The missense mutations are all located in known 









Figure 14. The nebulin gene and mutations identified within this gene. ** Finnish mutations 








Nonsense and frameshift mutations have been claimed to result in truncated nebulin 
molecules or nonsense-mediated mRNA decay. Immunohistochemical studies with 
antibodies against nebulin domains in the C-terminal region (Z-disc-binding region) and 
domains near the I band indicate, however, that a nebulin allele with mutations in the 3’ end is 
usually expressed and the C terminus of the protein is usually present.199, 255-257  One of the 
reasons explaining this, may be the differences in the efficiency of different termination 
codons and the nucleotides following it.258 In one sib pair with a homozygous nonsense 
mutation in exon 181, staining with an SH3 antibody detecting the last C-terminal domain of 
nebulin, was negative, whereas the other antibodies produced positive results.255 Such 
analyses have not been performed in cases of truncating mutations identified in the 5’ or mid-
region of nebulin. It remains to be established whether premature termination codons far from 
the normal stop codon result in nonsense-mediated mRNA decay.  
Table 3. Families with different forms of NM or other myopathies, and the types of nebulin 
mutations identified in them. Note that some of the mutations have been identified in more 
than one family and may underlie different forms of NM. 
SEV = severe, INT = intermediate, TYP = typical, OTH = other, UNK = unknown form of NM, 
DNM = distal nebulin myopathy, CRM = core-rod myopathy, n = number. ! the deletion of 
exon 55 is the same in all patients. i.f. = in-frame deletion, Hez = heterozygous, Hoz = 
homozygous *In one family one sibling has the intermediate and another the typical form of 
NM ; **The same mutation found both in homozygous and heterozygous form; *** the same 
mutation (in exon 171) causes the typical form of NM as compound heterozygous form in 
another family. **** The same mutation in ex171 identified in a proband classified as 















Families (n) 30 9 51 12 5 14 2 2 





























































































































The performed RT-PCR and minigene analyses (I) support the assumption that splice-site 
mutations would lead to skipping of one exon from the transcript. Although most transcripts 
lack one exon, a small proportion of the transcripts are normal, i.e. the splice-site mutations 
are leaky (I). Most (69 %) of the splice-site mutations, as well as the deletion of exon 55 (II), 
shorten a super-repeat with 35-66 amino acids, disrupting its organisation. This, in turn, is 
predicted to lead to impaired nebulin-tropomyosin interactions, and to reduce actin-binding 
sites in the molecule and thus to interfere with the contractile function of the sarcomere (I). 
The splice-site mutations in intron five, causing skipping of exon five, likely disrupt the N 
terminus of nebulin. This region binds to tropomodulin, a crucial capping protein defining the 
proper length of the thin filament at its pointed end.123, 144, 146, 259 The N-terminal mutations 
interfering with the tropomodulin-nebulin interaction may result in incorrect assembly and 
unstable thin filaments. A splice-site mutation leading to skipping of exon 3, in which the 
translation initiation codon lies, was identified in a patient with mild NM (unpublished). This 
indicates the possible usage of the next initiation codon (ATG) the transcription machinery 
encounters, i.e. codon 82 in exon 5. The same patient has another splice-site mutation on the 
other allele and this is predicted to cause skipping of exon 22 (unpublished). In addition to the 
mutated form of nebulin, the leaky nature of the splice-site mutations would result in normal 
nebulin isoforms also in the muscles of this patient, which may explain the mild disease 
phenotype. 
It is difficult to determine with certainty whether a missense change in nebulin is a 
pathogenic mutation or not. The missense mutations identified and presented here are all 
located in binding sites of actin or tropomyosin, or are predicted to affect the -helical 
secondary structure of nebulin.142 NEB is rich in polymorphic changes; over 200 SNPs and 
various di- or trinucleotide repetitions have been identified. The gene seems to be quite 
tolerant to missense changes and if the change does not alter a conserved amino acid, it is 
usually not expected to be harmful. On the other hand, some of the rare missense changes 
we have identified might be mutations, but due to lack of knowledge of all significant domains, 
e.g. binding sites of many proteins binding to nebulin, we cannot be sure whether the change 
is a SNP or a mutation. Hopefully, the ongoing functional analyses will shed light on the 
effects of these changes on the nebulin protein as well as on the pathogenesis caused by the 
known mutations. In addition, since nebulin is rich in polymorphisms, the significance of the 
different SNPs and haplotypes as modifiers of the phenotype is not known. Especially in very 
mildly affected patients with NM, it may transpire that some particular SNP or haplotype in fact 
affects the phenotype. Naturally, the surrounding genome and environmental factors modify 
the outcome of the disorder, as seen in the sib pairs with the same mutations but different 
phenotypes. Possible changes deeper in the introns, promoter or regulatory elements, in 






the cases where the first causative mutations have been detected but the second not. In 
addition, the new knowledge suggesting that nebulin has a significant role in Ca2+ 
homeostasis131 and subsequently in regulating muscle contraction diversifies the possible 
mechanisms through which mutations in NEB might lead to a muscle disorder. 
Project I revealed the true need for a method for effective NEB analysis. Using dHPLC 
and direct sequencing of DNA or, when possible, cDNA, we have detected more than 100 
mutations, some of them previously missed by SSCP. Careful optimisation of dHPLC is 
essential. We have identified three changes detectable at one, but not at another running 
temperature. Due to the nucleotide composition and sequence of some fragments, it is 
impossible to create conditions in which 100 % of the given fragment would be optimally 
analysed. dHPLC should, however, identify 98 % of changes despite the analysis conditions 
not being theoretically fully optimal.84 Since dHPLC detects any heterozygous change, it 
cannot distinguish between mutations and normal genomic variation. That a normal variation 
may mask additional changes in the DNA has been observed in at least one case. dHPLC is 
the most optimal method for scanning large numbers of patients for known mutations. The 
need for additional mutation analysis methods is due to: 1) NEB is a large gene, and using 
dHPLC or DNA sequencing only, the exons and exon-intron boundaries are covered. Large 
deletions, replications, insertions or inversions are missed, as well as mutations deeper in the 
introns possibly affecting the splicing of the gene. These kinds of mutations can be detected 
by RT-PCR, but usually no RNA source, i.e. muscle biopsy or myoblasts, is available. 2) 
Mutations further upstream in the promoter area or affecting the methylation. Such changes 
would go unidentified. We have been setting up the multiplex ligation-dependent probe 
amplification (MLPA) method in order to identify large copy number changes and changes in 
the methylation pattern of NEB. In addition, a project to design microarrays for mutation 
identification has been launched. Since it is such a gigantic, highly repetitive gene, NEB is 
very challenging to analyse. 
1.1 NEB mutations in Finnish NM families (I) 
To date, NM has been diagnosed in 21 families resident in Finland. In three of these families, 
however, one of the parents is not of Finnish origin. All parents are healthy which indicates 
that NM to is inherited in an AR fashion (or the mutations possibly to be de novo AD). One of 
the families has an ACTA1 mutation (de novo AD), another has a likely TPM3 mutation, and 
in three families no mutations have yet been identified. The remaining 20 patients from 16 
Finnish families have mutations identified in NEB; in six families the first mutation and in ten  






Finnish NM families with identified NEB mutations exhibit the typical form of NM. In family 11, 
one of the siblings has typical NM and another has the intermediate form of NM. In addition, 
the patient of family 3 has intermediate NM, while none have severe NM. The mutations 
identified include 15 different mutations (Table 4). None of the mutations have been found in 
homozygous form in any of the Finnish NM patients. Three of the mutations are shared by 
more than one NM family: a missense mutation (Ser to Ile) in exon 122 in nine families, a 
missense mutation (Thr to Pro) in exon 151 in three families, and a deletion of ten nucleotides 
in exon 122 in two families. The remaining mutations identified seem to be unique to each 
familiy. No two NM families share the same combination of mutations.  
Previous histological follow-up studies performed on the biopsies of 13 Finnish NM 
patients (all included in the NEB mutation analyses) detected clear histological changes 
between the first biopsy and the second biopsy taken 5-18 years later.222 Deficiency of type II 
fibres was seen in all of them except for the patients of three families (6, 11 and 13). In fact, 
the follow-up biopsies of the patients of these families showed hypertrophic type II fibres and 
small type I fibres.222 Families 11 and 13 have the same deletion of ten nucleotides in exon 
122. The second mutation in family 11 is the previously mentioned missense mutation in exon 
151, and in family 13 a splice-site mutation in intron 32. Family 6 has the missense mutation 
in exon 122 as the first mutation identified, while the second mutation is still unidentified. 
Thus, all of these families have a mutation in exon 122 but the nature of the mutations differ. 
It is difficult to draw any conclusions about why these patients have large type II fibres in 
addition to their small type I fibres while this is not the case in the other families who share 
the same exon 122 mutations. In addition, three patients from three families (1, 3 and 8) were 
using wheelchairs at the time the histological follow-up study was performed and showed, 
logically, small type I fibres and no hypertrophic fibres.222 They all have the missense 
mutation in exon 122 and, interestingly, two patients of families 1 and 3 have truncating 
mutations (different ones) in exon 163. The second mutation present in family 8 is yet to be 
identified. Patients in two separate non-Finnish families share another truncating mutation in 
exon 163. One of them has a severe and another has an unknown form of NM.222 
Comparisons of histological features between patients with NEB and ACTA1 
mutations did not reveal any clear differences in their fibre type proportions. Intranuclear rods, 
however, have to date been reported only in patients with ACTA1 mutations. As previously 
mentioned, ACTA1 mutations more often cause severe NM, while NEB mutations seem 
usually to cause typical NM. The ankle dorsiflexors have been shown to be especially weak in 
patients with NEB mutations while in patients with ACTA1 mutations, these muscles seem to 
be relatively spared. NEB mutations seem to affect knee extensors more than knee flexors 
with the situation being the opposite with the ACTA1 mutations. Otherwise, no clear general 






















Mis = missense mutation, Del = deletion, Dup = duplication, Non = nonsense mutation, Splice 
= splice-site mutation, T = typical NM, I = intermediate NM, C = CFTD, W = the patient uses a 
wheelchair. Mutation shared by two or more families highlighted by shaded background. The 
exact locations of the mutations in the genomic and protein sequences can be found in the 
corresponding article (I). 
Mutations  Family Form of NM; 
other notes Mis Del Dup Non Splice 
1  T ; W Ex122  Ex163   
2  T Ex122    In54 
3  I ; W Ex122   Ex163  
4  T Ex122    Int5 
5  T Ex122 Ex68    
6  T ; C Ex122     
7  T Ex122     
8  T ; W Ex122     
9  T Ex122     
10  T Ex151  Ex61   
11  I+T ; C Ex151 Ex122    
12  T Ex151     
13  T ; C  Ex122   Int32 
14  T  Ex61  Ex182  
15  T  Ex76  Ex173   
16  T    Ex142  
1.2 NEB mutations in Finnish distal nebulin myopathy families (III) 
Analyses of Finnish families revealed a novel, recessively inherited distal myopathy named 
distal nebulin myopathy (DNM) in six patients from four families, caused by two different 
homozygous missense mutations in NEB. The first mutation is the missense mutation in exon 
122 and the second is the missense mutation in 151 (both mentioned above). Combined with 
more disruptive mutations in compound heterozygotes, the same missense mutations cause 
NM. The muscle weakness in DNM involves predominantly the neck flexors, the lower leg 
and the finger extensor muscles (Fig 15), with the initial symptom being childhood or adult-
onset foot drop. The distribution of affected muscles differs from the weakness seen in NM 
caused by NEB mutations, and also from other inherited distal myopathies, such as tibial 
muscular dystrophy. As patients with Laing myopathy, however, show a similar distribution of 
muscle weakness as that of patients with DNM, Laing myopathy should be considered as the 






Figure 15. A. Atrophy of the tibialis anterior muscles and weakness ankle dorsifexion in 
patient with homozygous missense mutation (Thr to Pro) in exon 151. B. Atrophy of finger 
extensors of the patient with a homozygous missense mutation (Ser to Pro) in exon 151. 
 
Nemaline bodies (rods) are not detectable in the biopsies of the patients by LM. Some 
sections viewed under the EM (Fig 16) revealed Z-disc-derived aggregates, but they differ 
from nemaline bodies. 
 
 
Figure 16. Z-disc streaming visible in the 
biopsy of a DNM patient 
 
1.3 Genotype-phenotype correlations in patients with NEB mutations (I-III) 
Based on the results of the present study, it is still difficult to draw reliable conclusions about 
genotype-phenotype correlations in NM and related disorders. This might be difficult or even 
impossible until knowledge of all the important domains has been achieved and other proteins 






Tables 3 (p.56). and 4 (p.60), it can be seen that all types of mutations are involved in all 
forms of NM. In addition, mutations underlying different phenotypes have been identified all 
along the gene and in exons encoding super and simple repeats, as well as in alternatively 
spliced exons, in exons in the triplicated area, and in unique exons. 
Viewing and summarising the mutations causing the severe form of NM, it can be 
said that mutations in exon and intron 81 (the last exon before the triplication of the eight 
exons in the middle of the gene), and mutations in exon 180 (the last exon encoding the last 
simple repeat) seem to cause the severe form of NM. Of the 29 mutations causing severe 
NM, 19 have been found towards the 3’ end from exon 81 onwards. Six out of eight patients 
with the Ashkenazi deletion in homozygous form had severe NM, and two the typical form of 
NM (II). The typical form of NM is the most common form caused by mutations in NEB, with 
51 mutations identified to date in 42 families. A truncating duplication CAAA in exon 171 
caused the mild form of NM in one family when in the homozygous form, but combined with 
a nonsense mutation in exon 162, the same mutation has been found in a patient with the 
typical form of NM (I). Exon 171 is an alternatively spliced exon, which appears to be 
expressed in rare isoforms.151 Another truncating mutation in another family with mild NM is in 
exon 170 (I), which, too, is in a rarely expressed alternatively spliced exon.151 On the other 
hand, a homozygous truncating mutation in the alternatively spliced exon 173 causes the 
severe form of NM (unpublished). Exon 173 seems to be more commonly expressed than 
exons 170 and 171.151 
One of the families classified as having an unusual or “other“ form of NM is an 
interesting family with a sib pair affected with ophthalmoplegia, which is a very unusual 
symptom in NM. The first mutation identified in this sib pair was a small deletion in exon 58 (I), 
which is the only mutation identified in this exon to date. The second mutation remains to be 
found. It would be of interest to find out the cause of the eye muscle paralysis and studies 
towards this are ongoing. It might turn out that some regions in nebulin are essential for the 
specialised function of the eye muscles. It is also possible that these patients have an 
additional mutation in another gene. One patient belonging to the category of other forms of 
NM has a duplication TCAA in exon 171, and a nonsense mutation in exon 119 (I). A patient 
with core-rod myopathy has the same duplication in exon 171, and another truncating 
mutation in exon 140 (submitted). The combination of the two mutations thus affects the 
disease outcome. 
Until 2007, mutations identified in NEB were known to cause NM, only. The 
identification of DNM caused by homozygous missense mutations in NEB was possible due to 
the genetic isolation of Finland. This work not only described a novel myopathy, but showed 
that mutations in nebulin may cause disorders other than NM. Our recent data in fact provide 






myopathy in one patient. The milder outcome caused by homozygous missense NEB 
mutations in DNM seems logical, if missense mutations are considered to be less disturbing 
for the function of the protein. However, the overlap between the different NM forms caused 
by different/the same mutations and the mechanisms of nemaline body or core-rod formation 
remain to be resolved.  
2 Candidate gene and genome-wide linkage analyses (IV & V) 
2.1 Candidate gene analysis: Cap myopathy (IV) 
One of the aims of this project was to identify underlying genes in families with rare 
myopathies related to NM using a candidate gene approach. Sequencing genes known to 
cause similar myopathies, a mutation was identified in the -tropomyosin (TPM2) gene in a 
patient with cap myopathy. The histological overlap with NM suggested TPM2 to be the 
possible causative gene for this disorder, while immunohistochemical analyses performed on 
the biopsy of the patient displayed strong reactivity of the caps to nebulin. The mutation 
identified was a heterozygous in-frame deletion of one codon (delGAG) in exon 4 of the -
tropomyosin gene (TPM2), removing a single glutamate residue from the -tropomyosin 
protein (p.Glu139del). This is expected to disrupt the seven amino-acids long repeat essential 
for making a coiled coil, and thus to impair the tropomyosin-actin interaction. Sequencing 
TPM2 in the remaining six cap myopathy DNA samples in our sample cohort did not lead to 
the identification of other mutations. 
To date, 15 cap myopathy patients in 13 families have been reported (Table 1, p. 44). 
The discovery of families with members affected by both NM and cap myopathy (and some 
with unspecified muscle disorders)228, 230, 232 led to a discussion about the overlap between 
these entities; is cap myopathy a disorder of its own or is cap formation one histological 
feature of NM? Could the same genetic cause underlie these two disorders? Cap myopathy 
has previously established a position as an entity of its own. The patient of this study showed 
clinical and histological overlap both with previously reported cap myopathy patients and with 
NM patients; the distribution of muscle weakness was similar to that of patients with the 
typical form of NM, including facial weakness and both proximal and distal weakness of the 
limbs, as well as respiratory compromise out of proportion to his general muscle weakness. In 
addition, the MRI scan showed a pattern of thigh muscle involvement similar to that of NM 
patients with NEB mutations. However, neck and knee flexors, as well as rectus femoris, were 






present study was also different from that seen in the typical form of NM. An unusual feature 
in this patient was ptosis, which is not a common symptom either in NM nor in previously 
reported cap myopathy patients. 
After the identification of the initial cap myopathy-causing mutation, four additional 
mutations causing this disorder have been found in TPM2.232, 233 
2.2 Genome-wide linkage analysis in Turkish families (V) 
Twelve Turkish families with AR NM were included in a genome-wide linkage analysis using 
microsatellite markers, and subsequent mutational analyses were performed. As expected, 
the genome-wide scan revealed no haplotype shared by all the families included in the study. 
In fact, two different features were seen; those families in which the parents were cousins and 
originated from isolated populations (such as a village), displayed large homozygous regions 
covering areas too large to be analysed further. Another group of families did show promising 
homozygous regions, but subsequent fine mapping with additional markers failed to confirm 
the homozygosities, revealing false positive linkage in many chromosomal regions. This 
showed that the initial map of 300 markers (on average the markers were 10 cM apart from 
each other) was too sparse.  
One of the homozygous regions identified did, however, lead to the identification of a 
possible founder mutation in two of the families in the gene encoding -tropomyosinslow 
(TPM3), in the chromosomal region 1q12-21.2. Sequencing of this gene revealed a 
homozygous deletion in the muscle-specific, last exon of TPM3, c.913delA. This mutation 
resulted in severe NM in one and intermediate NM in another family. It was identified neither 
in the remaining Turkish families nor in the control individuals. The mutation was verified 
using RT-PCR showing expression of the mutant transcript. Unfortunately, no muscle 
biopsies, on which protein analysis could be conducted, were available from the patients with 
the mutation.  
The homozygous deletion of an adenine (c.913delA) removes the last nucleotide 
before the termination codon. A similar, but heterozygous, mutation previously reported to 
cause NM in a North American patient was analysed using Western blot analysis. This 
showed that reading through the termination codon leads to a longer protein product.260 As 
the mutation previously described,260 the mutation identified in this project changes the 
reading frame of the gene leading to read-through of the termination codon and likely to a 73 
amino acids longer protein. This longer protein is believed to be unable to form coiled-coil 






terminal regions of tropomyosins are essential for the proper head-to-tail polymerisation of the 
protein, but the the mutation might affect the acting-binding properties, as well.261, 262 
If the extended -tropomyosinslow is present in the patients’ sarcomeres, it should be 
non-functional, and the situation would be similar to the previously reported patient with a 
homozygous nonsense mutation Q31X in TPM3, and severe NM.263 In either case, the 
patients would have no functional -tropomyosinslow in their type I muscle fibres. This 
correlates with the histology of the patients’ muscle biopsies, showing severely hypotrophic 
type I muscle fibres. The patients should, however, express functional -tropomyosin in these 
fibres. Type II fibres, in which TPM3 is not expressed at all, are relatively unaffected. The 
altered protein in these patients is expressed and may affect the function of the two 
cytoskeletal isoforms of the gene expressed in small quantities also in other tissues,163 
possibly explaining some of the patients’ unusual clinical features. 
2.3 Mutations in TPM2 and TPM3 
The dimerised coiled-coil alpha-helix conformation, as well as polymerisation head-to-tail, are 
essential for the function of the tropomyosins expressed in the muscle sarcomere. The amino 
acids in the tropomyosin polymers, arranged into heptad repeats, must be in the exactly 
correct positions (a b c d e f g) for proper head-to-tail binding and for correct dimerisation of 
the pairing tropomyosins. The positions g and e of the opposite tropomyosins are bound 
together by salt bridges and act in stabilising dimer, and they point outwards from the 
molecule (Fig 8, p.32).157, 158, 261, 262, 264 Mutations in these positions may interrupt the 
formation of dimers. Other crucial regions, which have the potential to cause a disorder if 
interrupted, are the actin-binding residues of the tropomyosin in the outer surface acidic 
residues265 (such as the region of the E139del) and the tropomyosin-tropomodulin266 binding 
sites (Fig 19, p.70).  
TPM2 is expressed in both slow (type I), and, to a lesser extent, fast (type II) muscle 
fibres while TPM3 solely encodes the slow-specific isoform -tropomyosinslow.
127 This might 
be one of the explanations why TPM2 mutations are known to cause a variety of different 
disorders, while mutations in TPM3 are known to underlie two entities only. Mutations in 
TPM3 are known to cause NM and CFTD. The known TPM2 and TPM3 mutations and the 
disorders caused are listed in Tables 5 (p. 67) and 6 (p. 68), and shown in Figures 17 – 19 (p. 
67-69. Mutations in TPM1 are known to cause cardiomyopathies, but even though the gene is 







A variety of NMs, (distal) arthrogryposis, CFTD and cap disease are known to be 
caused by mutations in TPM2205, 217, 218, 270, 271(and personal communication with Prof. Anders 
Oldfors and Dr. Nigel Clarke) (Table 5, Fig 17, p. 67). Except for the situation in one family, 
the mutations are all dominant (mostly AD de novo mutations), and located in the exons 
expressed in all TPM2 splice variants. The only recessive mutation in TPM2 identified to date, 
a homozygous nonsense mutation causing NM associated with the Escobar syndrome, is in 
the muscle-specific exon 6B.271 Escobar syndrome is a rare disorder of orthopaedic and 
cranial anomalies, e.g. short stature, craniofacial anomalies, joint contractures, skin folds and 
low-set ears.272 In family 2 (Table 5), a mutation causes NM in one, and cap disease in 
another family member.232 Two TPM2 mutations seem to be recurrent: the mutation E139del 
first identified in the patient included in this PhD project (IV), has lately been identified as de 
novo AD in two more patients (supported by haplotype results): one with cap myopathy, and 
another with NM (unpublished data). Another recurrent mutation, R133W,270 recently 
identified in another patient, underlies two different forms of arthrogryposes (unpublished 
data). 
Mutations in TPM3 include both AR and AD mutations, and mutations have been 
identified both in muscle isoform-specific exons and in exons expressed in isoforms 
expressed in muscle and other tissues (Table 6, Fig 18, p. 68). TPM3 was the first gene to be 
identified to cause NM.198 The patients with TPM3 mutations include a clinically and 
histologically variable group of patients, but one common feature shared by the patients are 
small and abnormal type I fibres. The AD mutations in TPM3 result in milder forms of NM than 
AR mutations. The phenotype and the histology does, however, vary between the AR and AD 
NM cases and even between patients with the same mutation, as is the case with the patients 
described in this study.198, 221, 260, 263, 273, 274 The codon encodin to amino acid 168 of -
tropomyosinslow seems to be a mutational hotspot. It has shown to be mutated independently 
in different individuals six times due to different missense mutations affecting amino acid 168 






Table 5. TPM2 mutations expressed in -tropomyosin. All mutations except n:o 13 are 
dominant, and in exons expressed in all TPM2 variants. 
  Mutation  L Fam  Disorder 
1 p.K7del  g 1 NM*  




3 p.K49del  g 3 CAP233 
4 p.G52dup c 4 CAP233 
5 p.R91G  f 5 (possible) DA1218 
6 p.E117K  e 6 CFTD205, 217 
7 p.E122K c  CFTD**  









CAP i.p. & NM*** 
10 p.Q147P g 12 NM 205 
11 p.L148P a 13 NM***  
12 p.N202K f 14 CAP233 
13 p.Q210X 
homoz, AR 



















L = location in the coiled-coil.* personal communication with Dr. Nigel Clarke and ** Prof. 
Anders Oldfors, *** unpublished own data, i.p. = Clarke et al., 2009 in press (Neuromuscul. 









Figure 17. Alterations caused by mutations identified in -tropomyosin protein: Every other 
heptad repeat of the coiled coil in bold and underlined and every other as normal text. 








Table 6. TPM3 mutations expressed in -tropomyosinslow 
L = location in coil, nonm. = non-muscle, * = unpublished data. Mutational details can be found in 
the corresponding publications. 





1 p.M9R AD a muscle 1 NM198 
2 p.Q32X  
homoz AR 
c muscle 2 NM263 
3 p.S88F AD ? c muscle and nonm. 3 NM* 
4 p.L100M 
AD 
a muscle and nonm. 4 CFTD221 
5 p.R168H  
AD 






de novo AD  





de novo AD? 
f muscle and nonm. 10 CFTD221 
8 p.K169E  
de novoAD  
g muscle and nonm. 11 CFTD221 
9 p.R245G  
de novo AD   

















 muscle 14&15 NM (V) 
 
Figure 18. Alterations caused by mutations identified in -tropomyosinslow protein: Every other 
heptad repeat in the coiled coil is underlined and in bold and every other in thin. Alterations 









Figure 19. The locations of the alterations identified in the (slow)- and -tropomyosins 
caused by mutations in TPM3 and TPM2 respectively. The locations are estimations. The 
splice-site mutation (TPM3 n:o 10) is not shown. The alterations are numbered according to 
Tables 4 and 5. (Kindly provided by and modified with permission of Professor Anders 
Oldfors, University of Göteborg, Sweden) 
Conclusions and future prospects 
In this PhD study, NEB, TPM2 and TPM3 mutations were identified in patients with NM, cap 
myopathy or distal nebulin myopathy - a previously unidentified myopathy. 
At the time this project was launched, 18 mutations had been identified in 18 NM 
families; all had been found in the last 40 of the 183 NEB exons using SSCP. The mutation 
analysis of NEB was started at the 3’ end of the gene, because the corresponding region of 
the protein binds to the Z disc, from which nemaline bodies are derived. Previous linkage 
analyses, and the identification of only one AR mutation in NEB in eight families indicated that 
possibly tens of families within our sample series might have undiscovered mutations in NEB. 
It became obvious that more effective methods were needed in order to analyse all its 183 
exons. 
Optimisation of the dHPLC method and analysis of samples from 45 NM families 
revealed that NM-causing mutations could be found along the whole length of the gene, and 
that the vast majority of the patients have a unique combination of two compound 






different AR mutations in NEB, showing that NEB mutations truly are the most common cause 
of AR NM. 
In addition to these mutations, deletion of the exon 55 was identified in 2004 in the 
Ashkenazi population by Anderson’s group. During the course of the present study, the 
occurrence of this mutation was studied and estimated to be 2% among families with NM 
world-wide. In addition, it was shown that this mutation segregated with a haplotype shared 
by all the patients carrying the mutation. Although as many as 115 mutations have been 
identified in NEB, this is not enough to discern any reliable correlations between the severity 
of NM and the type of the NEB mutation. 
The identification of NEB mutations causing a novel myopathy, DNM, and of those 
causing core-rod myopathy, indicated that mutations in NEB might underlie other entities in 
addition to NM. It may well be that different types of mutations in NEB cause different entities. 
The pathological mechanisms which give rise to these different entities need to be elucidated 
in future studies. More mutations have to be identified and functional analyses performed to 
elucidate the possible molecular mechanisms leading to a variety of NM forms and other 
disorders. Novel mutation analysis methods, such as MLPA and microarrays will be required 
to detect all types of mutations in NEB, since changes in methylation patterns or large 
alterations such as deletions covering a whole exon, or several exons, cannot be detected 
using dHPLC.  
The previous and ongoing linkage and mutation analyses of known NM genes have 
show that there should be at least a seventh NM gene yet to be identified. A candidate gene 
as well as a genome-wide linkage approach was applied in this project in attempts to identify 
the seventh NM gene and to identify genes underlying those myopathies related to NM which 
have no genetic cause previously known. The sample cohort of the project included DNA 
samples from such patients with cap myopathy and core-rod myopathy. A systematic 
classification of these samples was conducted according to specific, often unusual, 
histological and/or clinical features and linkage analyses. Sequencing of the genes known to 
cause similar features in patients with other muscle disorders was then performed (published 
case reports or personal communications). This led to the identification of the first genetic 
cause, an AD de novo mutation in TPM2, underlying cap myopathy.  
At the time samples were chosen for the genome-wide linkage analysis, some twenty 
families showed no linkage to any of the known NM genes. Most of these families originated 
from Turkey, and therefore all the Turkish samples in our sample cohort were included in this 
study, which was performed using 300 microsatellite markers (the distance between the two 
markers being approximately 10 cM). Even the preliminary results of the scan showed large 
homozygous regions in several chromosomes in some of the families. Analysis of these 






positive results in the genome-wide scan, and further analyses showed some of the regions in 
fact, to be, heterozygous. No homozygous haplotypes or linkage were seen in most of the 
families, or the subsequent analyses “broke” the linkage/haplotype. In addition, only two of the 
families clearly shared the same haplotype in one of the chromosomes, i.e. chromosome 1, 
and the shared homozygous region in the patients of these two families was the region where 
TPM3 is located. Sequencing of TPM3 revealed a shared homozygous mutation disrupting 
the termination codon of the muscle-specific isoform of the gene. This is a likely founder 
mutation within the Turkish population. In order to identify the seventh gene using the 
samples from the families included in the microsatellite scan, a SNP scan would be the 
method of choice. 
The underlying reasons for the clinical and histological variability in patients with 
mutations in the same gene or even with exactly the same mutation, remain unclear. 
Examples are the families with cap and nemaline myopathy patients, the patients with 
homozygous deletion of the whole nebulin exon 55, or the patients from the two different 
Turkish families sharing the same homozygous mutation. On the other hand, many of the 
patients with mutations in different genes (in this context encoding different proteins in the 
muscle sarcomere) are clinically very similar. This means that examination of the phenotype 
does not alone permit identification of the causative gene. An example is the case with Laing 
distal myopathy and nebulin distal myopathy. A significant component of this variability may 
result from differences in splicing of alternative exons between different individuals, since 
creation of different isoforms through alternative splicing is extensive in both nebulin and the 
tropomyosins. Variability in expression of the different tropomyosin genes in different 
individuals, as well as the effects of other muscle genes, modifier genes and/or normal or 
abnormal variability in the genome may all influence the patients’ outcome. Moreover, even 
though the basic molecular structure and the functional principles of the skeletal muscle 
sarcomere have been known for decades, detailed molecular knowledge of both the structure 
and the events leading to muscle contraction remains to be elucidated. 
The exact molecular mechanisms behind the disorders caused by mutations in 
nebulin and the tropomyosins remain to be elucidated, but it is possible that some of the 
overlapping clinical features may be explained by shared pathogenetic pathways. Based on 
the present study, these kinds of mechanisms might cause aberrant interactions of the 








Table 7. Summary of the molecular genetic analyses performed and mutations identified 
during this study.  
 
                   Gene 
 
Disorder 
NEB TPM2 TPM3 
NM 
Families included (tot) 
 mutations identified in 
Mutations  
Studies I & II 
~ 150 
96   
115 (AR) 




Studies IV & V 
12 (+ 59 unpubl) 
2 (+ 2 unpubl) 
1 (AR) + (2 AD) 
DNM 
Families included (tot) 








Families included (tot) 





































Identification of the genes and mutations in great number of patients and correlating 
the clinical and the histological pictures to the mutations identified, is a prerequisite for 
understanding the pathogenesis of inherited disorders. This is essential for developing 
specific modes of treatments for these disorders. Mutation identification is often important for 
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Appendix 1: Codons and amino acids encoded 
 T  C  A  G  
TTT Phenylalanine (Phe)  TCT Serine (Ser)  TAT Tyrosine (Tyr)  TGT Cysteine (Cys)  T  
TTC Phe  TCC Ser  TAC Tyr  TGC Cys  C 
TTA Leucine (LeT)  TCA Ser  TAA STOP  TGA STOP  A 
T 
TTG Leu  TCG Ser  TAG STOP  TGG Tryptophan (Trp) G 
CTT Leucine (LeT)  CCT Proline (Pro)  CAT Histidine (His)  CGT Arginine (Arg)  T  
CTC Leu  CCC Pro  CAC His  CGC Arg  C 
CTA Leu CCA Pro  CAA Glutamine (Gln)  CGA Arg  A 
C 
CTG Leu  CCG Pro  CAG Gln  CGG Arg  G 
ATT Isoleucine (Ile)  ACT Threonine (Thr) AAT Asparagine (Asn)  AGT Serine (Ser)  T  
ATC Ile  ACC Thr  AAC Asn  AGC Ser  C 
ATA Ile  ACA Thr  AAA Lysine (Lys)  AGA Arginine (Arg)  A 
A 
ATG Methionine (Met) or START ACG Thr  AAG Lys  AGG Arg  G 
GTT Valine Val  GCT Alanine (Ala)  GAT Aspartic acid (Asp) GGT Glycine (Gly)  T  
GTC (Val)  GCC Ala  GAC Asp  GGC Gly  C 
GTA Val  GCA Ala  GAA Glutamic acid (Glu) GGA Gly  A 
G 
GTG Val  GCG Ala  GAG Glu  GGG Gly  G 
Abbreviations of the amino acids: 
Ala = A, Arg = R, Asn = N, Asp = D, Cys = C, Gln = Q, Glu = E,  Gly = G, His = H, Ile = I, Leu = L,  
Lys = K,  Met = M,  Phe = F,  Pro = P,  Ser = S,  Thr = T, Trp = W, Tyr = Y, Val = V  
 
